Mitochondria, cholesterol and cancer cell metabolism

Abstract

Given the role of mitochondria in oxygen consumption, metabolism and cell death regulation, alterations in mitochondrial function or dysregulation of cell death pathways contribute to the genesis and progression of cancer. Cancer cells exhibit an array of metabolic transformations induced by mutations leading to gain-of-function of oncogenes and loss-of-function of tumor suppressor genes that include increased glucose consumption, reduced mitochondrial respiration, increased reactive oxygen species generation and cell death resistance, all of which ensure cancer progression. Cholesterol metabolism is disturbed in cancer cells and supports uncontrolled cell growth. In particular, the accumulation of cholesterol in mitochondria emerges as a molecular component that orchestrates some of these metabolic alterations in cancer cells by impairing mitochondrial function. As a consequence, mitochondrial cholesterol loading in cancer cells may contribute, in part, to the Warburg effect stimulating aerobic glycolysis to meet the energetic demand of proliferating cells, while protecting cancer cells against mitochondrial apoptosis due to changes in mitochondrial membrane dynamics. Further understanding the complexity in the metabolic alterations of cancer cells, mediated largely through alterations in mitochondrial function, may pave the way to identify more efficient strategies for cancer treatment involving the use of small molecules targeting mitochondria, cholesterol homeostasis/trafficking and specific metabolic pathways.

Ribas et al. Clin Trans Med (2016) 5:22 DOI 10.1186/s40169-016-0106-5

Mitochondria, cholesterol andcancer cell metabolism

Vicent Ribas1,2, Carmen GarcaRuiz1,2,3 and Jos C. FernndezCheca1,2,3*

Introduction

Cancer cells exhibit critical metabolic transformations induced by mutations leading to gain-of-function of oncogenes and loss-of-function of tumor suppressor genes that result in cell deregulation associated with increased cellular stress. Hanahan and Weinberg identied the six conceptual hallmarks of human cancer: (1) self-sufficient growth signaling, (2) evasion of growth suppressors, (3) cell death resistance, (4) replicative immortalization, (5) angiogenesis and (6) invasion/ metastasis [1]. Other common characteristics of cancer cells include enhanced anabolism, avoidance of immune destruction and altered autophagy [2, 3]. Of these characteristic features of cancer cells, mitochondria are directly involved in a number of them. Indeed, mitochondria are

critical mediators of apoptosis and the source of reactive oxygen species (ROS) generation and energy production. Consequently, altered mitochondrial function of cancer cells underlies several phenotypes, including: (1) resistance to apoptosis; (2) increased biosynthetic anabolism to support uncontrolled growth and proliferation; (3) increased ROS generation that activates metastatic pro-teases, tumor-promoting inammation, genetic instability and DNA mutagenesis; (4) decreased mitochondrial oxidative phosphorylation (OXPHOS), increased aerobic glycolysis and decrease of pH in the extracellular milieu. Furthermore, due to its role as a hub in several signaling pathways [4], mitochondria are central for key metabolic alterations of cancer cells, some of which will be described below.

Experimental evidence indicates that high cell proliferation [5, 6] and tumor growth [7, 8] are closely associated with enhanced cholesterol requirement. Some types of cancers, such as hepatocellular carcinoma (HCC), are dependent on cholesterol for growth [9],

*Correspondence: [email protected]

2 Liver UnitHospital Clnic, Centre Esther Koplowitz, IDIBAPS, CIBEREHD, Planta Cuarta, C/Rossell 149, Barcelona 08036, SpainFull list of author information is available at the end of the article

2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/

Web End =http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Ribas et al. Clin Trans Med (2016) 5:22

Page 2 of 24

and observational studies show a protective association between the use of statins and the risk of developing liver cancer [10], although this trend has been also observed in other cancer types, such as prostate and gastrointestinal cancers [11]. In line with this, genome-scale metabolic models of hepatocellular carcinoma found that among 101 metabolites relevant to HCC development, 30% of them are related to cholesterol biosynthesis [12]. This protective eect of statins has been attributed to the inhibition of the mevalonate pathway (see below), preventing the posttranslational modication of the oncogenes MYC, RAS and RHO [11, 13, 14]. Moreover, analyses of the Cancer Genome Atlas (TCGA) database revealed a correlation between increased activity of the cholesterol synthesis pathway and decreased survival in patients with sarcoma, acute myeloid leukemia and melanoma [15, 16], supporting the concept that cholesterol promotes carcinogenesis. In this regard, cholesterol trafficking to mitochondria has been reported in tumor cells [17, 18] and may account for the recognized mitochondrial dys-function and contribute to chemotherapy and apoptosis resistance and metabolic reprogramming of cancer cells, which will be discussed in the following sections.

Mitochondria incell life anddeath Lifesustaining functions

Mitochondria are complex organelles, which dier from the often-held view of isolated, small rounded double-membrane structures. They constitute a dynamic network that continuously undergoes fusion and ssion controlled by specic mechanisms [19], and have interactions with other cell structures such as cytoskeleton and endoplasmic reticulum (ER) [20, 21]. Mitochondria contain multiple copies of their own maternally-inherited mitochondrial DNA (mtDNA), with an epigenetic complexity not completely understood [22]. Mitochondrial DNA is a circular molecule of approximately 16.5 kilobases present from hundreds to thousands of copies per cell, which encodes 13 polypeptides of the OXPHOS and respiratory chain, as well as 2 ribosomal RNAs and 22 transfer RNAs necessary for translation of polypep-tides inside mitochondria. Most mitochondrial proteins (approximately 1500) are encoded by nuclear DNA, translated in the cytosol and imported into the mitochondria through specic translocator complexes (TIM and TOM) of the mitochondrial inner (MIM) and outer membranes (MOM), respectively. In addition, a disulde relay molecular device consisting of MIA40 and augmenter of liver regeneration (ALR) are responsible for the import of nuclear encoded sulfur Fe/S cluster proteins to the mitochondrial intermembrane space that are essential for mitochondrial function [23, 24]. Recent data have shown that ALR links mitochondrial function to HCC

development [25, 26]. Indeed, mitochondrial proteome has signicant cell-type dierences, allowing mitochondria to serve in a highly adaptive fashion to the cellular specic functional requirements [27].

Mitochondria are the power plants of the cell, providing the energy for countless cellular functions through OXPHOS. OXPHOS is coordinated by a cascade of redox reactions organized in ve protein complexes embedded in the MIM, known as the electron transport chain (ETC), which transfers electrons to oxygen [28, 29]. The fall in electron potential energy through the ETC is used to pump protons out of the mitochondrial matrix to the intermembrane space, generating an electrochemical gradient known as the mitochondrial transmembrane potential (m), which induces a proton motive force used by complex V to regenerate ATP from ADP. Moreover, many additional mitochondrial processes, especially those related to transport of solutes across the MIM [30] are dependent on the electrochemical driving force of the m. Additional metabolic pathways that are located within mitochondria comprise the tricarboxylic acid cycle (TCA or Krebs cycle), -oxidation of fatty acids, steroidogenesis, metabolism of amino acids, formation of Fe/S clusters, heme biosynthesis as well as reactions involved in lipogenesis, gluconeogenesis, ketogenesis and ammonium detoxication (urea cycle) [31].

Physiologically under aerobic conditions, cells degrade glucose via glycolysis to pyruvate, which is imported into mitochondria. Pyruvate enters the TCA cycle in the form of acetyl-CoA that along with oxaloacetate generates citrate, in a reaction catalyzed by citrate synthase. Citrate is processed in the TCA cycle to generate reducing equivalents that feed the ETC and generate energy with the consumption of oxygen. However, in conditions where macromolecular biosynthesis is active, citrate may be exported to cytosol where is converted to acetyl-CoA by ATP citrate lyase (ACLY), which is used for lipogenesis. Besides their role in metabolism, mitochondria are involved in calcium homeostasis, innate immunity, integration of signaling pathways and autophagy [32, 33]. Moreover, in response to metabolic and genetic stress mitochondria and nucleus engage in bidirectional signaling pathways, which modulate cell function [4, 34, 35].

Electron transport through the ETC can leak the chain and react with oxygen to generate ROS [36, 37]. Complex I and complex III are the major sources of mitochondrial ROS generation [28], although other mitochondrial sites also contribute to ROS production, including complex II [38]. The existence of an efficient antioxidant defense system, of which mitochondrial glutathione (mGSH) is a central component, prevents or repairs oxidative damage generated during normal aerobic metabolism [39]. The primary ROS generated in mitochondria is

Ribas et al. Clin Trans Med (2016) 5:22

Page 3 of 24

superoxide [40], which is produced in the mitochondrial matrix and undergoes dismutation to hydrogen peroxide (H2O2) [40], a reaction catalyzed by mitochondrial superoxide dismutases (SOD2). Hydrogen peroxide is further inactivated by the mitochondrial glutathione peroxidase (mGSH/GPX) and peroxiredoxin/thioredoxin (Prx/Trx) antioxidant systems [41]. Both systems use the reducing equivalents of NADPH to regenerate the mitochondrial oxidized glutathione (mGSSG) and Trx back to the reduced forms. The Prx/Trx system is thought to be responsible for scavenging hydrogen peroxide at nanomolar concentrations, while mGSH/GPX system is important for buering high ROS levels [42, 43]. However, both systems are mutually regulated, as selective depletion of mGSH results in decreased levels of Trx2 and Prx3 [44], highlighting the central role of mGSH in maintaining an adequate hydrogen peroxide homeostasis. Due to its more stable and diusible nature, hydrogen peroxide acts as a second messenger because of its reactions with specic oxidation-prone protein cysteinyl residues [45], which confers properties to hydrogen peroxide as a mitochondrial signaling molecule [4]. In line with this, mitochondrial hydrogen peroxide bursts have self-sustained circadian oscillations, acting as a redox intracellular pacemaker [46].

Death promoting pathways

Besides their fundamental role in energy generation, mitochondria also play a strategic role in the regulation of several forms of cell death, including apoptosis (both caspase-dependent and independent), necrosis and programmed necrosis [47]. The central mediators of apoptosis include a group of cysteine proteases named caspases, which become activated by a proteolytic processing cascade in response to pro-apoptotic signals. The series of events leading to apoptosis have been categorized in two modes, the extrinsic and intrinsic apoptotic pathways. The extrinsic pathway involves extracellular ligand binding to a transmembrane death receptor, such as TNF receptor or FAS receptor, followed by recruitment of cytosolic adaptor proteins and activation of an initiator caspase (usually caspase-8), which stimulates an eector caspase (such as caspase-3). Conversely, the intrinsic (or mitochondrial) pathway involves the destabilization of the MOM and the release of mitochondrial proteins that activate eector caspases. The BCL-2 family of proteins regulates this pathway with opposing pro-apoptotic eector functions (BAX, BAK), pro-apoptotic BH3-only proteins (BAD, BIM, BID, BIK, Noxa, PUMA, HRK, BMF) and anti-apoptotic functions (BCL-2, BCL-xL, MCL-1, A1, BCL-B, BCL-w) [48]. Activation of the intrinsic pathway of apoptosis by a number of stimuli and stresses, triggers the binding and activation of pro-apoptotic proteins

BAX or BAK to the MOM leading to the MOM permeabilization (MOMP) without disruption of the inner membrane and the subsequent release of proteins from the mitochondrial intermembrane space (IMS), such as cytochrome c [49, 50]. Although active BAX or BAK are required to induce MOMP, the underlying mechanism is controversial [51]. While the model of pro-apoptotic activation or neutralization by anti-apoptotic members are still incompletely known, recent ndings have shown that BCL-2 ovarian killer (BOK), which displays a high sequence similarity to BAX and BAK, engages the mitochondrial apoptotic pathway independently of BAK/ BAX [52]. Although mitochondrial proteins are normally secured in the IMS the rupture of the physical barrier (MOM) constitutes a point-of-no-return in cell death [49, 50]. Pro-apoptotic BH3-only proteins act as stress sentinels that relay the diverse array of apoptotic signals via BAX/BAK activation to induce MOMP. In contrast, anti-apoptotic BCL-2-family proteins prevent MOMP and apoptosis by binding BH3-only proteins, preventing their interaction with BAX/BAK, or by binding activated BAX/BAK [53]. Pro- and anti-apoptotic BCL-2 protein interactions are mediated between BH-3 domains and the BH3 binding cleft in anti-apoptotic BCL-2 proteins.

Once released from the mitochondria into the cytosol through MOMP, cytochrome c binds to the adaptor molecule APAF-1, causing it to oligomerise and form a heptameric structure called apoptosome [54]. This complex recruits pro-caspase 9, which in turn, activates the executioner caspases-3 and -7, triggering the cascade of events that lead to controlled cell death and fragmentation. In addition to cytochrome c, other IMS proteins (Table 1) are also mobilized and released into the cytosol following MOMP where they promote or counteract caspase activation and hence cell death [5560].

Table 1 IMS proteins related toapoptosis induction

IMS protein MW (kDa) Function References

Cytochrome c 12 Apaf1 binding and apoptosome initia tion

[49, 54, 56]

[49, 56, 57]

SMAC/DIABLO 23 Neutralization of apoptosis inhibitor factors

[49, 58]

AIF 62 DNA fragmentation [56, 59] ENDOG 28 DNA fragmentation [55] AK2, Adenylate

Kinase 2

OMI/HTRA2 37 Neutralization of apoptosis inhibitor factors

[60]

26 Initiation of AK2 FADDcaspase10 complex

Ribas et al. Clin Trans Med (2016) 5:22

Page 4 of 24

For the execution of mitochondrial apoptosis cytochrome c detaches from the MIM and dissociates from the phospholipid cardiolipin, which binds cytochrome c by an electrostatic bond [61]. Cardiolipin can be oxidized by ROS or by the cardiolipin cytochrome c complex [62] resulting in oxidized cardiolipin, which exhibits lower affinity for cytochrome c than the reduced form, and therefore contributes to cytochrome c detachment from MIM and its release to cytosol. Since mitochondrial ROS are controlled by anti-oxidants [63, 64], mGSH arises as an important modulator of apoptotic cell death by indirectly controlling the redox state of cardiolipin [63, 65]. In addition, it has been described that oxidized cardiolipin modulates the biophysical properties of MOM to allow oligomerized BAX to insert and permeabilize the MOM [63, 65, 66].

Integrin-mediated attachment of normal cells to the extracellular matrix elicits anti-apoptotic and pro-survival signaling. The loss of cellmatrix interaction induces anoikis, a specic form of apoptosis [67]. Cell detachment leads to upregulation and activation of several BH3-only pro-apoptotic proteins (BID, BIM and BDF) that, in turn, activate BAX and BAK resulting in MOMP and the apoptotic cascade, resulting in cell death [68]. In addition to MOMP, the generation of mitochondrial ROS in cells undergoing anoikis is required for cell death, as antioxidants treatment suppressed anoikis [69, 70]. Normal cells detached from the matrix undergo dramatic global metabolic changes characterized by decreased mitochondrial respiration and SOD2 induction. Indeed, cells depleted of SOD2 are hypersensitive to cell death by anoikis [71], suggesting the importance of ROS generated in mitochondria in the execution of anoikis.

As opposed to apoptosis, necrosis is a morphologically distinct form of cell death responsible for irreversible tissue destruction due to bioenergetic failure and oxidative damage. Permeabilization of the MIM by the mitochondrial permeability transition (MPT) and secondary rupture of the MOM is a key event of necrosis. MPT is a regulated pore-forming protein complex whose molecular characterization remains elusive [7274]. Of the MPT components, cyclophillin D is a key constituent, while the role of other putative components, such as voltage-dependent anion channel (VDAC), adenine nucleotide translocase (ANT) and translocator protein (TSPO, also called benzodiazepine receptor, PBR) is controversial [49, 75, 76]. Mitochondrial ROS regulate MPT by targeting specic cyclophillin D cysteine residues. Necrosis is characterized by mitochondrial swelling, loss of m, and impaired OXPHOS and ATP generation.

The fundamental dierence with respect to apoptosis is the rapid loss of cellular membrane potential due to

energy depletion and ion pump/channel failure, leading to swelling and cytolysis. Concomitantly, water inux causes matrix swelling, rupture of MOM and release of apoptogenic proteins sequestered in IMS. These events, however, block apoptotic cell death due to energetic failure, ATP exhaustion and oxidative stress-mediated caspase inactivation. Moreover, TNF has been recently shown to induce a caspase-independent form of programmed cell death, named programmed necrosis or necroptosis [77, 78], involving receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 kinases, which interact with the pseudokinase mixed lineage kinase domain-like protein (MLKL). The execution of necroptosis requires mitochondrial ROS generation, which is dependent of MPT and involves cyclophyllin D but it is independent of BAX or BAK [79].

Cholesterol homeostasis andmitochondrial traffickingCholesterol synthesis andderegulation incancer cells

Cholesterol is an essential component of membrane bilayers that plays a key role in their integrity and function. While intake of cholesterol from the diet ends up in different cell membranes, the predominant mechanism that provides the cholesterol needed for cellular functions is its de novo synthesis from acetyl-CoA in the so-called mevalonate pathway, which generates not only cholesterol but also non-sterol components, such as dolichol, ubiquinol and isoprenoids. The hydroxymethylglutaryl-CoA reductase (HMGCoAR) catalyzes the reduction of HMG CoA to mevalonate, the rate-limiting step in the synthesis of cholesterol [80]. Mevalonate is phosphorylated to pyrophosphomevalonate, which is then converted to isopentenyl pyrophosphate (IPP). IPP can be reversibly transformed to dimethylallylpyrophosphate (DMAPP), which can combine with IPP to generate the 10-carbon isoprenoid geranyl pyrophosphate (GPP). The secuential addition of 1 or 2 more IPP units to GPP generates farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), respectively. Isoprenoids generation in the mevalonate pathway is an essential mechanism of posttranslational modication of proteins and these lipid moieties anchor target proteins to cell membranes. FPP is used to prenylate proteins of the Ras family, while GGPP prenylates those of the Rho family [81]. In addition, FPP can be converted into squalene by squalene synthase (SS), which catalyzes the rst step in the committed pathway for cholesterol synthesis. Statins, whose chemical structure is similar to that of HMGCoA, compete with and inhibit HMGCoAR, preventing the formation of mevalonate and its downstream product IPP. Therefore, the therapeutic eects of statins can extend beyond cholesterol inhibition and impact in the regulation of a number of proteins due

Ribas et al. Clin Trans Med (2016) 5:22

Page 5 of 24

to the blockade of isoprenoids (FPP and GGPP) generation. In contrast to statins, the inhibition of SS results in selective cholesterol downregulation without exerting a major eect in the isoprenylation of proteins [82].

As HMGCoAR is the regulatory enzyme in the mevalonate pathway its feedback and transcriptional control impact in cholesterol and isoprenoids regulation. One mechanism for feedback control involves the rapid degradation of HMGCoAR mediated by ER resident proteins, Insigs. Accumulation of sterols in the ER membrane triggers binding of the membrane domain of HMGCoAR to a subset of Insigs, which carry a membrane-anchored ubiquitin ligase called GP78 which ubiquitinates HMGCoAR, marking it for proteasomal degradation [83]. HMGCoAR is regulated at the transcriptional level by the transcription factor SREBP-2, which resides in the ER is an inactive form. When sterols levels are low, SREBP-2 is transported from the ER to the Golgi to undergo a proteolytic processing by specic proteases, resulting in the mature form of SREBP-2, which translocates to the nuclei to induce HMGCoAR as well as other targets involved in the regulation of cholesterol homeostasis, including the LDL receptor.

As cholesterol synthesis requires oxygen, which is used for the biotransformation of squalene to cholesterol, an additional mechanism that regulates cholesterol synthesis is oxygen availability. Indeed, the bulk for the oxygen requirement centers on the sequential transformation of lanosterol to cholesterol, involving several redox reactions. Moreover, hypoxia has been shown to stimulate HMGCoAR degradation through both accumulation of lanosterol and Insigs induction [84]. In contrast to these physiological features, cholesterol synthesis and regulation are altered at several levels in cancer cells to meet the unrestricted growth needs [8487]. Indeed, tumor cells exhibit increased cholesterol levels compared to surrounding cells; moreover, cancer tissues display increased upregulation of HMGCoAR, loss of feedback inhibition, decreased expression of cholesterol exporter ATP binding cassette transporter A1 (ABCA1) and increased extracellular cholesterol uptake via LDL receptor [87]. Hence, as briey described below (Strategies targeting the mevalonate pathway and cholesterol synthesis in cancer section), targeting the mevalonate pathway may be of potential relevance in cancer therapy.

Mitochondrial cholesterol trafficking incancer

Mitochondria are cholesterol-poor organelles compared to other cell bilayers (e.g. plasma membrane). Nevertheless, the limited availability of cholesterol in the MIM plays an important physiological role, including the synthesis of bile acids in hepatocytes or steroid hormones in specialized tissues through the metabolism

of mitochondrial cholesterol by CYP27A or CYP11A1, respectively. In pathological conditions, however, the accumulation of cholesterol in mitochondria alters membrane organization and the coexistence of lipid-disordered and lipid-ordered phases, which regulates membrane permeability and function of resident proteins [88]. Of relevance, increased mitochondrial cholesterol levels have been described in solid tumors. For instance, mitochondrial cholesterol levels of tumors from Bualo rats bearing transplanted Morris hepatomas are two to vefold higher than the content found in mitochondria prepared from host liver, and correlated with the degree of tumor growth and malignancy [89, 90]. As mitochondrial cholesterol in cancer cells contribute to the alterations in mitochondrial function and properties, understanding the mechanisms governing the trafficking of cholesterol to mitochondria may be of relevance in cancer cell biology. In this regard, given its lipophilic properties and water insolubility, non-vesicular transport by specic carriers stands as the major mechanism of cholesterol transport between organelles. In particular, mitochondrial cholesterol transport is preferentially regulated by the steroidogenic acute regulatory domain 1 (StARD1), the founding member of a family of lipid transporting proteins that contain StAR-related lipid transfer (START) domains [91]. StARD1 is a MOM protein, which was rst described and best characterized in steroidogenic cells, where it plays an essential role in cholesterol transfer to MIM for metabolism by CYP11A1 to generate pregnenolone. Despite similar properties with StARD1, other StART members cannot replace StARD1, as germline StARD1 deciency is lethal due to adrenocortical lipoid hyperplasia [92]. Moreover, targeted mutations in MLN64 (StARD3), another START member with wide tissue distribution, impair steroido-genesis while causing minor alteration in cholesterol metabolism [93]. Furthermore, analyses of the TCGA database further support a role for StARD1 and MLN64 and subsequent mitochondrial cholesterol enrichment in cancer development. Although MLN64 is an endosomal protein, it participates in the egress of cholesterol from endosomes to mitochondria [94], suggesting that MLN64 and StARD1 work in concert to ensure the trafficking of cholesterol to MIM. Increased StARD1 expression and mitochondrial cholesterol loading are causally linked as StARD1 silencing decrease mitochondrial cholesterol levels in hepatocellular carcinoma [17]. Moreover, decreased ABCA1 activity has been reported in colorectal cancer cells either through loss-of-function or gene downregulation and ABCA1 downregulation promoted cancer cell survival by increased mitochondrial cholesterol accumulation [95]. Thus, these ndings indicate that the trafcking and accumulation of cholesterol in mitochondria is a characteristic feature of many types of cancer and its

Ribas et al. Clin Trans Med (2016) 5:22

Page 6 of 24

role in carcinogenesis may be related to the regulation of cell death and chemotherapy sensitization, which will be described below.

Role ofmitochondria andcholesterol inaltered cancer cell metabolism

The oncogenic transformation of cancer cells requires energy metabolism reprogramming in order to support unrestrained growth. The dependence on aerobic glycolysis despite normal oxygen tension constitutes one of the key metabolic alterations in cancer cells. This event was rst described by Otto Warburg in 1930 and has ben coined since then as the Warburg Eect [9698]. Although the glycolytic phenotype in cancer cells was proposed to be due to defective mitochondrial OXPHOS, many cancer cells exhibit competent OXPHOS activity capable to generate ATP [99]. The dependence on glycolysis is characteristic of many tumors and is widely exploited for clinical tumor imaging using positron emission tomography (PET) with a radiolabeled analog of glucose (18F-uorodeoxyglucose) [100]. Elevated aerobic glycolysis in cancer cells serves many purposes, ensuring ATP generation without reliance on oxygen availability. Moreover, aerobic glycolysis generates bicarbonic and lactic acids, which are released to the extracellular milieu, favoring tumor invasion, angiogenesis and immunosurveillance suppression [101]. Glucose can be diverted to the pentose phosphate pathway to generate nucleotides and NADPH to fuel antioxidant defenses and biosynthetic reactions. Finally cancer cells use intermediates of glycolytic pathway for biosynthesis of de novo nucleic acids, lipids and amino acids to support their unrestrained growth and proliferation [97, 102, 103]. In line with these changes, a Warburg-like metabolism has been described in many rapidly proliferating embryonic tissues, supporting the biosynthetic programs of aerobic glycolysis in active proliferating cells [104, 105]. Given that many tumor types rely on oxidative metabolism, glucose ux is not necessarily coupled to oxidative glucose metabolism. Oxygen consumption in many cancer cells is used for mitochondrial oxidation of alternate fuels, such as glutamine [106], suggesting that the fate of glucose for mitochondrial oxidation in cancer cells is probably even lower. Cancer cells undergo a number of metabolic alterations, including the depression of oxidative mitochondrial OXPHOS and TCA cycle, which are used for anabolic reactions [107, 108]. Moreover, several transcriptional and posttranslational mechanisms have been proposed to contribute to the metabolic reprogramming and dependence on the Warburg eect in cancer cells, involving activation of oncogenes and inactivation of tumor suppressor genes. In this regard, activated oncogenes such as KRAS and MYC along with mutated

tumor suppressors such as TP53 can extensively reprogram cell metabolism resulting in diversion of carbon skeletons to fuel anabolic reactions for biomass synthesis instead of being completely oxidized through mitochondrial respiration.

MYC intumor metabolism reprogramming

MYC is an oncogene that plays a role in cell cycle progression, apoptosis and cellular transformation. In addition, MYC is important for the increased transcription of metabolic enzymes required for anabolism in cancer and fast-growing cells, regulating the conversion of glucose to pyruvate through the activation of important glycolytic genes and glucose transporters, while blocking the entry of pyruvate into the TCA cycle via pyruvate dehydrogenase kinase (PDK1). Interestingly, MYC promotes the metabolic adaptation of tumor cells [109] by activating genes important for mitochondrial biogenesis and function [110, 111]. Moreover, the AMPK-related protein kinase 5 (ARK5), which is involved in maintenance of mitochondrial integrity and bioenergetic homeostasis, was identied as a MYC target [112]. This dual role of MYC as a driver of Warburg eect and a promoter of mitochondrial biogenesis underlies the dependence of cancer cells on glutamine oxidation, an essential event for cell survival under conditions with low glucose and oxygen [113]. Moreover, MYC upregulates the glutamine transporters SLC5A1 and SLC7A1, which contribute to glutamine uptake in cancer cells. As MYC induces the ux of 3-phosphoglycerate from glycolysis to the synthesis of serine and glycine needed for nucleotide biosynthesis, MYC coordinates the synthesis of nucleotides with glutamine metabolism [114]. Indeed, the rate of glutaminolysis is greater compared to the rate of glycolysis in cells with high MYC expression and are more dependent on mitochondrial oxidative metabolism than cells with low MYC levels.

Tumors are metabolically heterogeneous, exhibiting complex metabolic proles [115], including the dependence on aerobic glycolysis and reliance on OXPHOS [116119]. For instance, while cancer stem cells are quiescent and exhibit high OXPHOS reliance, they may coexist with other highly cycling cancer cells that rely on glycolysis. The dependence of these cancer stem cells on mitochondrial OXPHOS prompted the use of mitochondrial OXPHOS inhibitors to selectively target these cells to prevent tumor relapse after cytotoxic treatment [120, 121]. It has been described that in pancreatic tumors MYC acts as a switch between the OXPHOS-dependent metabolism of cancer stem cells towards the highly glycolytic dierentiated progeny, creating a gradient of heterogeneous oxidative/glycolytic population inside the tumor. Moreover, MYC acts as a direct transcriptional

Ribas et al. Clin Trans Med (2016) 5:22

Page 7 of 24

inhibitor of peroxisome proliferator-activated receptor (PGC1-) suppressing mitochondrial respiration while activating glycolytic programs [119]. This heterogeneity denes a scenario where therapies targeting specically highly respiratory or highly glycolytic tumor cells may not be completely eective.

TP53 andtumor metabolism

Reduced expression of the tumor suppressor protein TP53 can also impact metabolic reprogramming in cancer cells. Defects in P53 function lead to impaired trans-activation of SCO2, a mitochondrial protein required for the correct assembly of the cytochrome c oxidase in the ETC and of TIGAR, an isoform of 6-phosphofructo-2-kinase, whose expression exerts a tumor suppressor function by inhibiting glycolytic ux [122, 123]. Moreover, TP53 activates transcription of glutaminase 2 (GLS2) to promote glutaminolysis to fuel the TCA cycle and facilitate fatty acid oxidation as an alternative source [124]. Collectively, TP53, in addition to its role in orchestrating cell cycle arrest and apoptosis, counteracts the Warburg eect by favoring OXPHOS and minimizing glycolytic metabolism, and therefore its loss-of-function is a requirement for the aerobic glycolysis in most carcinogenic processes.

Hypoxiainducible factor (HIF1)

Hypoxia is an inherent feature of solid tumor development that arises due to the disorganized structure and architecture of tumor vasculature resulting in irregular and inefficient oxygen delivery. Hypoxia is considered a negative prognostic factor for response to treatment and survival of cancer patients [125, 126]. Hypoxia-inducible factor (HIF) is a key transcription factor activated mainly by hypoxia due to the dependence of HIF-proly hydroxylases (PHD) on oxygen (see below). In addition to hypoxia HIF is also regulated by oxidative stress, inammation and metabolic stress [127]. HIF1 comprises a stable subunit (HIF-1/Arnt) and a labile subunit (HIF1) encompassing three family members, HIF1, HFI2 and HIF3 (Fig.1). In normoxia HIF1 is rapidly degraded due to the sequential action of oxygen-dependent PHD and the Von Hippel-Landau E3-ubiquitin ligase (pVHL). PHDs primarily function as oxygen sensors so that in normoxia PHDs become activated to hydroxylate HIF1 on two highly conserved proline residues. Hydroxylated HIF1 is then recognized and ubiquitinated by the pVHL, marking HIF1 for proteasomal degradation (Fig.1a). In low oxygen conditions, PHDs are inactivated and therefore HIF1 is stabilized, translocate to the nucleus where heterodimerize with HIF1/Arnt to form a complex that activates hundreds of genes involved in energy metabolism, autophagy and angiogenesis [128]

(Fig.1b). Activation of HIF1 promotes the conversion of glucose to pyruvate and lactate by upregulating the transcription of glucose transporters (GLUT1), hexokinases (HK1 and HK2), lactate dehydrogenase A (LDHA) as well as the lactate-extruding monocarboxylate transporter 4 (MCT4) [129], supporting the shift to aerobic glycolysis. Activated HIF1 increase the transcription of the PDK1, which inhibits PDH, decreasing the conversion of pyruvate to acetyl-CoA, which compromises OXPHOS, therefore linking low oxygen conditions to the depression of mitochondrial function. Moreover, HIF-1 activates transcription of the cytochrome c oxidase subunit 4-2 (COX4-2) and the LON mitochondrial protease, which degrades COX4-1 subunit and allows its substitution by the less efficient COX4-2 subunit [130]. In a scenario with inhibited mitochondrial OXPHOS by genetically down-regulating the master regulator of mitochondrial biogenesis PGC1, ROS-mediated HIF1 stabilization is able to rescue cell bioenergetics by activating transcription of glycolytic genes and glycolysis, allowing cancer cells to escape from metabolic stress [131]. In addition, HIF1 induces the expression of BCL-2/adenovirus E1B 19-kDa interacting protein 3 (BNIP3) and BNIP3-like (BNIP3L), which trigger mitochondrial autophagy, thereby decreasing the oxidative metabolism of both fatty acids and glucose [132]. Therefore, HIF1 not only counteracts the MYC-mediated suppression of mitochondrial biogenesis by reducing mitochondrial mass and function, but also cooperates with MYC to promote aerobic glycolysis by induction of HK2 and PDK1 [133]. There are three PHDs known in mammals, encoded by three genes (PHD1, PHD2 and PHD3) [134]. Although, PHDs are thought to act as true oxygen sensors due to their requirement of oxygen for hydroxylation of HIF1, they are also dependent on iron (Fe2+), ascorbate and on the TCA intermediate 2-oxoglutarate (2-OG) as cofactors. Conversely, it has been reported that several TCA intermediates, such as fumarate and succinate competitively inhibit all three PHDs, while citrate and oxaloacetate inhibit factor inhibiting HIF1 (FIH), an asparaginyl hydroxylase which is able to block the transcriptional activity of HIF1 by catalyzing the hydroxylation of an asparagine residue of HIF1 [135]. These eects have important implications as succinate dehydrogenase (SDH) inactivation and isocitrate dehydrogenase (IDH) neomorphic gain-of-function leading to accumulation of succinate and 2-hydroxyglutarate, respectively, contribute to HIF1 stabilization and cancer promotion [136].

Role ofROS incancer cell biology

The impact of ROS in cancer research is controversial due to their dual role in promoting tumor growth, angiogenesis and metastasis or supression of tumor development,

Ribas et al. Clin Trans Med (2016) 5:22

Page 8 of 24

Ribas et al. Clin Trans Med (2016) 5:22

Page 9 of 24

depending on the context and on the type of species generated [137140]. ROS are highly reactive molecules with the potential to target and oxidize proteins, lipids and DNA, which derive from dierent sources and mechanisms (Table2) and from environmental events, such as ultraviolet or ionizing radiation [39, 139, 141].

ROS-induced damage on DNA can lead to enhanced mutation rates, driving the transformation of normal cells into a tumorigenic phenotype. In line with this association, moderate intake of antioxidants have shown to reduce the risk of cancer development and slow cancer progression [142145], leading to the concept that anti-oxidants can prevent ROS-induced damage and therefore cancer incidence. Moreover, high ROS production in

cancer cells can stabilize survival factors such as HIF1, which drive tumor initiation and progression [146]. Solid tumor formation, in turn, contributes to hypoxia development due to the disorganized vasculature, and the limited oxygen supply in solid tumors stimulates mitochondrial ROS generation and HIF1 stabilization [147, 148]. HIF1 in turn activates ROS generation, establishing a feed-forward loop where HIF1 supports its stability to promote cancer cell survival and malignant progression [141]. However, transformed cells adapt to this oxidative environment by turning on strategies that control the generation of ROS to ensure their role in proliferation signaling, while containing the damaging eects of ROS overproduction. An important strategy in this regard is the modulation of mitochondrial ROS generation, which is downregulated in cancer cells by shifting to aerobic glycolysis. This scenario suggests that reducing mitochondrial oxidation not only promotes survival of cancer cells but also increases anabolic metabolism. On the other hand, the pro-apoptotic activity of mitochondrial inhibitors are reversed by antioxidants [121, 149], lending further support for the association of ROS with tumor prevention [141]. Conversely, large-scale multicenter clinical trials of antioxidant supplementation showed a signicant increase in cancer incidence [150 154]. Quite intriguingly recent preclinical studies conrmed the pro-tumorigenic and pro-metastatic eects of antioxidant supplementation such as N-acetyl-l-cysteine (NAC), a GSH precursor [155, 156], thus highlighting the relevance of antioxidants in the protection of cancer cells against oxidative damage. Therefore, antioxidant supplementation can promote the growth of tumors by rescuing the viability of cells under high oxidative stress.

A key survival strategy of cancer cells is the upregulation of antioxidant systems to detoxify the production of ROS. One central factor associated to the resistance of cancer cells is the transcription factor NF-E2-related factor (NRF2). NRF2 is a master regulator of the antioxidant response and xenobiotic metabolism through the regulation of a wide range of antioxidant and detoxication genes [157]. NRF2 is sequestered in the cytoplasm by the Kelch-like ECH-associated protein 1 (KEAP1), which acts as a NRF2 repressor and plays a pivotal role in the regulation of the NRF2 pathway. KEAP1 binds and promotes NRF2

Table 2 Cellular sources ofROS

Source Cellular compartment

Primary radical generated

Complex IF Mitochondria O2

Complex IQ Mitochondria O2

Complex IIF Mitochondria O2

Complex IIQ0 Mitochondria O2

mGPDH Mitochondria O2

ETFQOR Mitochondria O2

PDH Mitochondria O2

OGDH Mitochondria O2

BCKDH Mitochondria O2

P66shc Mitochondria, cytoplasm H2O2

NOS Cytoplasm NO NOX family Cytoplasm, cell membrane O2

Xantine oxidase Cytoplasm, peroxisome H2O2

Cytochrome p450 family Endoplasmic reticulum O2

H2O2

CIF complex I avin site, CIQ complex I ubiquinone site, CIIF complex II avin site and CIIIQ0 complex IIIQo are sites of the mitochondrial ETC, mGPDH Mitochondrial glycerol 3-phosphate dehydrogenase, ETFQOR electron-trasferring avoprotein ubiquinone oxidoreductase, PDH pyruvate dehydrogenase,OGDH 2-oxoglutarate dehydrogenase and BCKDH branched-chain 2-oxoacid dehydrogenase are mitochondrial enzymes capable of generate ROS. Upon stress signaling, cytosolic p66Shc translocates to mitochondria to directly stimulate hydrogen peroxide generation. Nitric oxide synthase (NOS) produces NO.by facilitating the conversion of L-arginine to L-citruline. NADPH oxidase family of enzymes (NOX) transfer electrons from NADPH to O2 to produce

O2. Other cellular enzymes incuding xanthine oxidase and cytochrome p450 families also participate in ROS generation in normal biological reactions and in chemicals or xenobiotics detoxication reactions

Ribas et al. Clin Trans Med (2016) 5:22

Page 10 of 24

degradation through the ubiquitinproteasome pathway. Under oxidative stress or through particular chemical inducers, cysteine residues of KEAP1 are modied and the resulting conformational change leads to the release of NRF2, which is stabilized and translocated to the nucleus, to induce the transcription of a large number of genes [158]. In this regard, NRF2 activators, such as curcumin, butylated hydroxyanisole (BHA) or the synthetic oleane triterpenoids (CDDO), have preventive properties against carcinogenesis [157]. However, given the dual role of ROS on cancer genesis and development, NRF2 activation also provides protection to cancer cells. Therefore, NRF2 is constitutively elevated in many types of cancer cells [159162] and this increase is associated with a poor prognosis in cancer patients [163165]. A variety of molecular mechanisms contribute to the constitutive expression and/ or stabilization of NRF2 in cancer cells. Loss-of-function by somatic mutations or epigenetic silencing of KEAP1 impairs its binding to NRF2 and abrogates its repressive eect [159, 166]. The autophagy protein P62, also named sequestrosome 1, binds and sequesters KEAP1 in autophagosomes, leading to the autophagy-dependent KEAP1 degradation, resulting in increased NRF2 stability and activation of target genes [167170]. Overexpression of P62 or increased P62 levels due to defects in autophagy leads to persistent activation of NRF2 [171, 172], contributing to carcinogenesis [173]. In addition, activation of oncogenes such as K-RAS, BRAF and MYC stimulates the transcription of NRF2 [174]. There is substantial evidence that impaired TCA cycle activates NRF2 [175], in a similar fashion as described for HIF1. In this case, fuma-rate accumulation can form adducts with KEAP1 on its cysteine residues and provoke NRF2 activation. Physiological fumarate levels are low due to the activity of fumarate hydratase (FH). However, in cancer cells with loss-of-function of FH, high levels of fumarate are associated with sustained NRF2 activation [176, 177]. Nonetheless, activation of NRF2 transcriptional activity leads to the upregulation of antioxidants and detoxifying enzymes that promote not only the survival of cancer cells but also mediate chemoresistance [178, 179]. Besides these important roles of NRF2 on detoxication, it has also been shown that NRF2 can contribute to other aspects of cancer survival such as the counteraction of cell death by BCL-2 overexpression [180] and altered metabolism by redirecting glucose and glutamine to the production of ribose-5-phosphate for nucleotide synthesis and to the regeneration of NADPH through the activation of the pentose-phosphate pathway [181].

Besides the role of ROS scavenging in cancer progression, this event is also important for cancer metastasis. Hence, it can be postulated that the supplementation of antioxidants would provide an additional advantage

for cancer cells to spread to distant sites by counteracting their sensitivity to anoikis and oxidative stress. For instance, metastatic cells undergo reversible metabolic changes that allow them to counteract oxidative stress [156, 181]. Indeed, it has been recently shown that increased GSH synthesis mediates the metastatic colonization of colorectal cancer cells to the liver [182]. Conversely, other reports showed that inhibition of mitochondrial oxidative stress prevents metastasis [183, 184] and this apparent paradox might be explained by the different targets of antioxidants and their eect in dierent types of cancer cells [184186]. Therefore, current anti-oxidant strategies are not clinically eective in cancer therapies, illustrating our limited understanding on the complex role of ROS in tumor initiation, progression and metastasis, which needs to be fully characterized to identify new and more eective therapeutic venues.

Mitochondrial cholesterol inHIF1 regulation

As mentioned above, HIF-1 is the main transcription factor regulating the cellular response to hypoxia and its stabilization is known to promote cell survival and tumor progression. While HIF-1 stabilization is mainly determined through oxygen sensing by PHD and iron availability, PHD activity is also dependent on the cytosolic levels of 2-OG. Indeed, 2-OG emerges as a potential inhibitor of angiogenesis and cellular transformation by promoting the degradation of HIF1 [187, 188].

HIF-1 activation contributes to the metabolic reprogramming of cancer cells by impairing mitochondrial phosphorylation and the subsequent stimulation of aerobic glycolysis. Although the physiological levels of mitochondrial cholesterol are low, mitochondrial cholesterol accumulation impairs mitochondrial function and the activity of the mitochondrial 2-oxoglutarate carrier (2-OGC), which exchanges cytosolic GSH by matrix 2-OG. As StARD1 promotes mitochondrial cholesterol accumulation in the inner membrane, StARD1 induction thus contributes to the impairment of OGC carrier, resulting in the depletion of 2-OG in the cytosol and GSH in the mitochondrial matrix (Fig.2). As mentioned above, mGSH is a key mitochondrial antioxidant that controls hydrogen peroxide production [39, 189, 190]. Moreover, mitochondrial ROS generation has been shown to promote HIF-1 stabilization [147, 191]. Thus, it is conceivable that StARD1 induction and the subsequent accumulation of cholesterol in mitochondria result in the depletion of cytosolic 2-OG, impairing PHD activation and subsequent HIF-1 stabilization. Therefore, mitochondrial cholesterol loading may have an important role in cancer cell survival by a dual eect through impairment in mitochondrial function and dynamics, while promoting HIF1 stabilization via depletion of

Ribas et al. Clin Trans Med (2016) 5:22

Page 11 of 24

cytosolic 2-OG levels and generation of mitochondrial ROS. As a result, mitochondrial cholesterol loading in cancer cells acts as an additional mechanism governing angiogenesis and novel vessel growth via HIF1 stabilization, although this molecular link deserves to be further tested and it is currently under investigation. Finally, his-tone lysine demethylases have been recognized as important players in cancer cell biology by removing methyl moieties from DNA and aberrant expression of these chromatin modifying enzymes is implicated in the course of tumor initiation and progression [192]. Like PHD, his-tone methyl demethylases are also dependent on iron and 2-OG, and therefore mitochondrial cholesterol loading may further modulate cancer progression by the regulation of histone lysine demethylases via limitation of cytosolic 2-OG levels, which deserves further investigation.

Role ofmitochondria andcholesterol incancer cell death andchemotherapy resistanceMitochondria andcell death resistance

Cancer cells have evolved multiple mechanisms to disable programmed cell death to support their survival and proliferation. Given that mitochondria are key players in several pathways of programmed cell death (see above) many strategic battles regulating cell death resistance take place in mitochondria [49]. The most prominent example of

this is the overexpression of pro-survival BCL-2 proteins, a common feature in diverse cancers. The gene encoding BCL-2 was rst identied in a chromosomal translocation that resulted in constitutively high levels of BCL-2 in neoplastic B cells [193, 194]. Dierent mechanisms such as genomic copy number amplication, oncogenic transcriptional upregulation or downregulation of microRNA repressors or stabilization of BCL-2 family members contribute to the maintenance of high levels of Bcl-2 [195, 196]. On the other hand, due to genomic deletion or promoter methylation leading to transcriptional silencing, loss-of-function of several pro-apoptotic proteins such as BAK, BAX and BH3-only family members have been observed in a variety of cancer types. Although BAX and BAK can play redundant roles, recent experimental data argues that in the context of activation of BH3-only protein or anti-apoptotic BCL-2 there is a strict dependence of either BAX or BAK [197, 198]. Although cancer cells are generally resistant to apoptosis, certain stress conditions, such as hypoxia and low nutrient availability, lower the threshold for apoptosis susceptibility. Cancer cells often exhibit higher levels of pro-apoptotic BH3-only protein, which is accompanied by higher anti-apoptotic BCL-2 proteins to antagonize apoptosis. This state has been termed as cancer cells primed for death [199] and this dependence on anti-apoptotic BCL-2 proteins can be

Ribas et al. Clin Trans Med (2016) 5:22

Page 12 of 24

exploited to design more eective pro-apoptotic therapeutic strategies [200].

Lossof-function of TP53 is found in more than 50% of human cancers. In addition to the above-mentioned roles of its inactivation in cancer cell metabolism, TP53 is central in the orchestration of cell death pathways upon cellular stress such as DNA damage by stimulating the transcription of pro-apoptotic proteins (PUMA, BAX), autophagy and cell-cycle arrest. TP53 exerts a vast array of extranuclear functions and therefore the cytoplasmic pool of TP53 cooperates with its nuclear counterpart to activate programmed cell death in response to certain cellular stresses. TP53 is involved in various forms of cell death such as apoptosis, necrosis and necroptosis and is able to mediate both MOMP and MPT opening in response to death stimuli. After stress induced TP53 activation, a small fraction translocates to MOM, resulting in the activation of the intrinsic apoptotic pathway [201]. TP53-mediated MOMP is related to the ability to bind and inactivate anti-apoptotic BCL-2 and BCL-xL, and to transcriptionally induce the expression and activation of pro-apoptotic proteins by direct binding [202]. Moreover, TP53 regulates MPT openings of necrosis/necroptosis via cyclophillin D and dynamin-related protein 1 (DRP1) [203, 204] in response to specic cell death triggers, such as TNF or oxidative stress. In addition, TP53 inhibits autophagy [205], resulting in impaired mitophagy, contributing to the reduced threshold for cell death. Given these protective roles against specic alterations in cell cycle and cell death resistance, many cancer-associated TP53 mutations have been identied. Although most of TP53 mutations has been described as loss-of-function, it has been proposed that some TP53 mutations may have oncogenic capabilities [206].

Although MOMP is considered a point of no return for apoptosis, cancer cells are able to inhibit caspases ensuring survival in certain conditions. This mechanism described in some post-mitotic cells, such as neurons and certain cancer cells, allows the recovery of cancer cells provided that MOMP-inducing stimuli are removed [207209]. Caspases can be directly inhibited by XIAP or by the neutralization of its inhibitors [200]. In addition, cytochrome c released through MOMP can be targeted for proteasomal degradation thereby avoiding the assembly of the apoptosome [209]. Besides caspase inhibition, survival after MOMP requires a pool of intact mitochondria in which MOMP has not been triggered [210]. The selective maintenance of cells with intact mitochondria may contribute to carcinogenesis and cancer relapse after cytotoxic therapies due to the increased susceptibility to oncogenic transformation [211]. Moreover, limited mitochondrial permeabilization induced by sub-lethal apoptosis triggers can promote DNA damage, genomic

instability and ultimately carcinogenesis [212, 213]. This mechanism would have two important implications for cancer progression. First, low-level limited apoptosis can drive mutagenesis in surviving cancer cells, serving as a driving force towards malignancy. Second, sub-lethal apoptotic anticancer therapies can increase the tumorigenic potential of surviving cancer cells by promoting new mutations that favor relapse and chemotherapy resistance.

Mitochondrial cholesterol incell death andchemotherapy resistance

As mentioned above, cholesterol trafficking to mitochondria has been reported in tumor cells, including mitochondria from HCC due to overexpression of StARD1 [17]. Mitochondrial cholesterol loading in cancer cells may account for the recognized mitochondrial dysfunction and resistance to BAX-mediated cell death induced by chemotherapeutic agents that target mitochondria to elicit MOMP. In line with this, treatments that resulted in mitochondrial cholesterol loading in tumor cells impaired stress-induced apoptosis [17, 18], while StARD1 knockdown or treatments that resulted in down-regulation of cholesterol loading sensitized HCC cells to chemotherapy [17]. Isolated mitochondria from HCC with increased cholesterol levels have been reported to be resistant to MOMP and release of cytochrome c or smac/DIABLO in response to various stimuli, such as MPT triggers and active BAX. In agreement with these ndings, HeLa cells treated with the amphiphilic amine U18666, which perturbs intracellular cholesterol trafficking and stimulates mitochondrial cholesterol accumulation, impairs MOMP and the release of cytochrome c in response to BAX [18]. Furthermore, ABCA1 downregulation determines resistance to chemotherapy through increased mitochondrial cholesterol accumulation [95]. Similar behavior was observed in cholesterol-enriched mitochondria or liposomes and reversed by restoring mitochondrial membrane order or cholesterol extraction. Cholesterol inhibited the membrane-permeabilizing activity of tBID/BAX or BAX pre-oligomerized with octylglucoside in a dose-dependent manner. Similar to the eect found on BAX, cholesterol also decreased the permeabilizing activity of melittin, a widely studied antimicrobial peptide, which induces membrane permeabilization by forming lipid-containing toroidal pores rather than through the formation of protein channels [17]. These ndings indicate that cholesterol-mediated decrease in membrane uidity of the bilayer directly modulates BAX pro-apoptotic activity by reducing the capacity of BAX to insert into the lipid matrix of the membrane, underlying the anti-apoptotic role of mitochondrial cholesterol accumulation in cancer cells. Thus,

Ribas et al. Clin Trans Med (2016) 5:22

Page 13 of 24

mitochondrial cholesterol contributes to chemotherapy resistance in HCC by increasing membrane order and resistance of MOM to MOMP. As StARD1 regulates mitochondrial cholesterol trafficking, it is conceivable that this member of the StART family stands as a novel target to regulate cancer cell death and chemotherapy response.

Cancer biology andtherapeutics

As described in the previous sections, cancer cells exhibit critical metabolic transformations induced by mutations that result in cell cycle deregulation associated with enhanced cellular stress. Adaptation to this stress phenotype is required for cancer cells to survive and involves the participation of genes that regulate metabolism, bioenergetics, cell death and ROS detoxication

(Fig.3). In this context, small molecules that selectively kill cancer cells while sparing normal surrounding cells, are the desired approach for the treatment of cancer. To this aim, cancer therapeutics should target the dierential features of cancer cells. Here, we briey summarize the therapeutic strategies that involve mitochondria and their proposed mechanism of action to selectively target transformed cells.

Therapeutics aimed atcancer metabolism andbioenergetics

Cells are addictive to glucose and glutamine and their limitation can cause cell death. This dependence is driven by the activation of MYC and HIF1- [109] and consequently, targeting pathways regulating glucose/ glutamine metabolism may be of relevance for cancer

Ribas et al. Clin Trans Med (2016) 5:22

Page 14 of 24

treatment. The specic GLS1 inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulde (BPTES) inhibits proliferation of lymphoma cells but has no eect on neuroblastoma cells, which express GLS2 [214, 215], implying that the general GLS inhibitor 6-diazo-5-oxo-L-norleucine (DON) may exhibit broader antitumor eects [216, 217]. Inhibitors of glutamate dehydrogenase (GDH) are promising agents to target glutamine addiction of certain cancer cells. For instance, the green tea component epigallocatechin-3-gallate (EGCG), which inhibits GDH, has been shown to promote apoptosis in several cancers types, resulting in tumor growth inhibition, setting the basis for the exploration of its efficacy in phase II clinical trials [214, 218].

The inhibition of aerobic glycolysis in cancer cells is also of potential relevance. While inhibitors such as 2-deoxy-d-glucose and ionidamine, which targets early steps in the glycolysis pathway, exhibit severe toxic side eects [218], inhibition of distal steps in glycolysis are eective. Inhibition of lactate production by inactivation of lactate dehydrogenase (LDH) reduces tumorigenicity in several cancer models [219221]. Additionally, the specic inhibitor of LDHA, FX11, reduces tumor progression in lymphoma invivo [219]. In some cancers LDHB can replace LDHA, hence limiting the efficacy of the LDHA inhibitors [109, 222]. Inhibition of lactate export from cancer cells results in wide-reaching consequences, leading not only to lactate accumulation, alterations in glycolytic intermediates, reduction in glucose transport and ATP, NADP and GSH levels but also in mitochondrial damage and cell death [223], suggesting that inhibition of lactate transporter MCT1 is a suitable therapeutic approach. Moreover, the eect of small molecules that block the entry of pyruvate to the mitochondrial TCA cycle, such as dichloroacetate, a PDK1 inhibitor, may be of potential relevance [109, 218, 224].

Although targeting glycosis may be eective in a specic population of cancer cells exhibiting a highly glycolytic dependence, stem cancer cells that rely on OXPHOS might become resistant. Moreover, although mitochondrial oxidation under the Warburg eect is dramatically reduced, many cancer cells still have a central requirement on mitochondrial metabolism, strongly suggesting that OXPHOS inhibitors might represent an important target for drug-resistant cancers [121]. A key agent with potential relevance in inhibiting OXPHOS is metformin, one of the most prescribed drugs around the world for the treatment of type II diabetes [225228]. Metformin is an indirect activator of AMP-activated Kinase (AMPK) through inhibition of mitochondrial complex I, resulting in the activation of the ATM/LKB1/AMPK axis. LKB1 is a well-characterized tumor suppressor in pancreatic, lung cancer and melanoma. AMPK activation

inhibits the mTOR pathway and this eect accounts for the potential antineoplastic eects of metformin in breast and renal tumors. Moreover, metformin reduces glycolysis and increases mitochondrial respiration in tumors, and these events are associated with growth arrest [229]. In addition, metformin exhibits antiangiogenic eects, which contribute to its antineoplastic properties [230]. Other compounds with mild OXPHOS inhibition such as tamoxifen, which also inhibits complex I, resveratrol, which antagonizes complex III, and the complex V inhibitor 3,3-diindolylmethane have potential in cancer treatment. VLX600 is a novel compound targeting OXPHOS that inhibits tumor growth of colon carcinoma cells, thus exhibiting potential application in clinical trials [231]. Besides, a number of emerging mitochondrial inhibitors successfully used in experimental studies could be eective against cancer cells and might synergize with chemotherapeutics [149, 232, 233].

Therapeutics targeting cancer cell death

Given that BCL-2 is overexpressed in many tumors, most strategies to engage apoptosis pathways are based in the blockade of anti-apoptotic members of the BCL-2 family. BCL-2 inhibitors have been developed based on the structure of BH3-binding groove of BCL-xL [234], leading to the development of the prototypic BH3 mimetic that displays sub-nanomolar affinity for BCL-xL and a binding prole similar to the BH3-only protein BAD. The BH3 mimetic ABT-737 and the more soluble analogue ABT-263 bind BCL-xL, BCL-2 but not MCL1 and both show antitumor activities either as single agents or in combination [235]. However, the clinical applicability of these BH3 mimetics is limited due to severe thrombocytopenia mediated by platelet apoptosis [236, 237]. ABT-199, a novel BH3 mimetic developed from the structure of ABT-263 [238], is eective in chronic lymphocyte leukemia. A potential side eect of ABT-199 is the induction of tumor lysis syndrome [239], which can be controled by step-wise dose escalation. Although the therapeutic results with BH3 mimetics are promising, resistance is a potential drawback. For instance, BCL-2 mutations that abrogated binding of BH3 mimetics mediate resistance of ABT-199 in experimental lymphoma models [240]. As BCL-2 inhibitors do not target MCL-1, a key anti-apoptotic BCL-2 member, the efficiency of BH3 mimetics may be limited, particularly in the treatment of solid tumors [241243]. Hence, the combination of specic MCL1 inhibitors [244, 245] with BH3 mimetics is a promising therapeutic approach to overcome chemotherapy resistance. Moreover, as MCL-1 plays a key role in mitochondrial physiology and autophagy, targeting MCL-1 may cause undesirable side eects [246, 247]. For instance, the toxicity of pan-BCL-2 inhibitors, such as Gossypol or

Ribas et al. Clin Trans Med (2016) 5:22

Page 15 of 24

Obatoclax, which inhibit BCL-2 and MCL1, prevented the evaluation of their efficacy in clinical settings [243]. These ndings suggest that MCL1 inhibition should be ne-tuned and that the relative contribution of BCL-2-family components to the apoptosis resistance of cancer cells should be carefully evaluated through the BH3 proling to determine the therapeutic window [248, 249]. In addition, incomplete cell death caused by triggers of mitochondrial apoptosis can promote genomic instability and mutagenesis derived from the incomplete MOMP and caspase-dependent DNA cleavage, contributing to tumor relapse and the acquisition of drug resistance [212, 213]. Based on the ability of TP53 to induce apoptosis, mitochondrial targeted TP53 fusion proteins have been developed to induce intrinsic apoptosis in cancer cells, which may be of relevance in adjuvant therapy for cancer treatment [201, 250]. Overall, targeting or sensitizing cancer cells to apoptosis is a promising strategy currently under development, which may lead to personalized medicine through specic tumor-proling and ne-tuning dosage and therapy combinations.

Therapeutics targeting cancer cell ROS sensitivity

Despite generation of higher ROS levels cancer cells are more sensitive to intracellular ROS induction than untransformed cancer cells. Many cancer chemotherapeutic agents, including taxanes, vinca alkaloids, platinum coordination complexes, paclitaxel and elesclomol are currently used to induce high levels of ROS to kill cancer cells [251]. The ultimate eect of these molecules is determined by the intrinsic antioxidant capacity of cancer cells as the cytotoxic potential of these agents is lost upon antioxidant co-treatment [252254].

A key mechanism to counteract the generation of ROS by chemotherapeutic agents is the regulation of GSH homeostasis [137, 182]. Several small molecules, which modulate ROS, such as -phenethyl isothiocyanate (PEITC), buthionine sulphoximine (BSO), curcumin or CDDO derivatives, have potential therapeutic eects for the treatment of cancer by promoting mGSH deletion and subsequent ROS generation specically in cancer cells [255258]. BSO, an inhibitor of glutamate-cysteine ligase, which is the rate-limiting enzyme in GSH biosyn-thesis [259] is the only clinically used drug to suppress the novo GSH synthesis. The simultaneous administration of BSO and the thioredoxin inhibitor auranon induce ROS and clonogenic killing in carcinoma cells [260]. Sulfasalazine, which inhibits cystine uptake via XcL carrier, limits cysteine availability impairing GSH biosynthesis, which leads to reduced growth and viability of cancer cells invitro and invivo [261, 262]. In addition, specic mGSH depletion has also been associated with apoptosis induced by chemotherapeutic drugs. For example,

the triterpenoid methyl CDDO derivative (CDDO-Me), induces cytotoxicity in chemotherapy-resistant myeloid leukemia cells and this event is associated with selective depletion of mGSH, resulting in increased ROS generation [263, 264]. Moreover, PEITC depletes mGSH and consequently increases ROS and nitric oxide, contributing to inhibition of the mitochondrial complex I, suppression of mitochondrial respiration, and subsequent cytotoxicity of leukemia cells [265]. Using a cell-based small-molecule screening and quantitative proteomics, piperlongumine has emerged as a cytotoxic agent that triggers apoptosis and necrosis in leukemia cells [266]. Interestingly, piperlongumine induces ROS generation and cell death in transformed cells but not primary normal cells [267]. Piperlongumine also decreases GSH and increases GSSG levels in cancer cells without eects in nontransformed cells, and these eects parallel the ability of piperlongumine to alter mitochondrial morphology and function. Consequently, co-treatment with piperlongumine and NAC prevented piperlongumine-mediated GSH depletion and cell death in cancer cells. These ndings support the concept that cancer cells have high levels of ROS, and hence, have a strong reliance on the ROS stress-response pathway driven by NRF2.

At present, radiotherapy is widely used in various types of cancer treatments, and the therapeutic eect is mainly determined by ROS generation. The induction of water radiolysis occurs in seconds after ionizing radiation, lasts several hours after exposure and enhances ROS generation and oxidative stress [268, 269]. Some studies suggested that antioxidant supplementation could sensitize cancer cells to chemo- or radio-therapy and reduce their side eects by protecting the normal cells [270]. However, other studies indicated that antioxidants may also protect cancer cells against these therapies [252, 271, 272]. Therefore, the safety and efficacy of the combined treatment of antioxidants with radiotherapy or ROS-inducing chemotherapy remain controversial.

Strategies targeting the mevalonate pathway andcholesterol synthesis incancer

As described above, cancer cells exhibit alterations in the regulation of cholesterol homeostasis and de novo synthesis in the mevalonate pathway. Despite that the main therapeutic benet of statins is the prevention of cardiovascular diseases and heart attacks, the use of statins has been associated with lower incidence of colorectal carcinoma, melanoma, prostate cancer and HCC, although the benet of statins in other types of cancer has been disappointing [273]. While statins inhibit cholesterol synthesis, they also aect other intermediates of the mevalonate pathway, including isoprenoids, and therefore the benecial eects of statins in cancer may be independent

Ribas et al. Clin Trans Med (2016) 5:22

Page 16 of 24

of cholesterol synthesis. For instance, statins inhibit the activation of the proteasome pathway, contributing to the maintenance of proteins that block cell cycle. Through cholesterol downregulation, statins regulate the function of Hedgehog, a signaling pathway involved in carcinogen-esis [273]. Besides these wide-reaching eects of statins, their benet in cancer treatment is limited due to the complex regulation of HMGCoAR and the metabolites generated in the mevalonate pathway. Reduction of isoprenoid and cholesterol levels in cancer by chronic treatment with statins leads to upregulation of HMG-CoAR levels and eventually development of resistance [274]. Invitro mechanistic studies of statins used signicantly higher concentrations than those that were therapeutically achievable in phase I trials. Dose-limiting toxici-ties, including gastrointestinal side eects, myelotoxicity, myalgias, elevation of creatine phosphokinase and hepatotoxicity, precluded further dose increase in clinical trials [275]. Inhibition of SS has attracted much interest as a pharmacological target as it implies the inhibition of cholesterol synthesis without depressing isoprenoid levels. For instance, lapaquistat (TAK-475, Takeda), a SS inhibitor, progressed to phase III clinical trials, although its outcome in cancer remains to be established due to hepatotoxic eects at high dosing [276]. As mentioned before, prenylation is a key postranslational mechanism of targeted proteins, and many prenylated proteins are involved in various aspects of carcinogenesis, including cellular proliferation, apoptosis, angiogenesis and metastasis. Farnesylation is catalyzed by farnesyltransferase (FTase) and geranylgeranylation by geranylgeranyltransferase, GGTase. Given the role of protein prenylation in carcinogenesis, FTase inhibitors (FTIs) and GGTase inhibitors (GGTIs) have been developed for cancer treatment. GGTIFTI combinations synergistically inhibit proliferation of multiple myeloma cell lines and primary cells, and induce apoptosis. Interestingly, dual prenylation inhibitors (DPIs) that block both FTase and GGTase enzymatic activities have been shown to induce apoptosis in PSN-1 pancreatic tumor cells by blocking K-Ras prenylation compared to either FTI or GGTI agents alone [277]. H and N-Ras prenynation is eectively inhibited by FTIs and only partially by GGTIs, whereas K-Ras prenylation requires both FTIs and GGTIs inhibition [278]. Thus, combined inhibition of geranylgeranylation and farnesylation can overcome the resistance conferred by cross-prenylation, thus potentiating the activity of either FTIs or GGTIs alone. Finally, targeting the specic targeting of cholesterol to mitochondria may be an additional approach of potential benet in cancer treatment by modulating cell death and chemotherapy resistance. This specic eld is currently under investigation to identify potential specic inhibitors of StARD1 and MLN64

to sensitize cancer cells to cell death triggers and chemoterapeutic agents.

Conclusions andfuture approaches

Cancer cells undergo an array of genetic and epigenetic modications that lead to a phenotype characterized by high proliferation, death resistance, rapid growth and invasiveness. Mitochondria play an essential role in metabolism, bioenergetics and cell death regulation and consequently oncogenic modications characteristic of many cancer types mediate the array of metabolic alterations of cancer cells by impairing key mitochondrial functions. This continuum evolving process in the adquisition of a highly proliferative phenotype requires the selection of cells with decreased mitochondrial oxidation of fuels, relying on the oxidation of glucose for ATP generation, resulting secondarily in the engagement of the pentose phosphate pathway as a source of reducing equivalents needed for anabolism and antioxidant defense. These metabolic alterations are accompanied by the involvement of mitochondria in biosynthetic pathways to support continuous growth, while reducing the deleterious eects of high-rate production of ROS, a characteristic feature of cancer cells. Furthermore, mitochondria undergo changes in membrane dynamics, exemplied by the decrease in membrane uidity to protect cancer cells against the induction of programmed cell death triggered by the immune system or by metabolic or xenobiotic stresses. A key player in this event is the accumulation of cholesterol in mitochondria of cancer cells, which increases the threshold for MOMP by restructuring mitochondrial membrane bilayers. Besides this function, mitochondrial cholesterol accumulation may indirectly contribute to the metabolic changes of cancer cells by impairing mitochondria function and activation of survival programs turned on by HIF1 activation. Given these functions of mitochondrial cholesterol, preventing or reversing this process may be of relevance in cancer cell biology to shift the balance towards increased apoptosis susceptibility and sensitization to chemotherapy. In addition, oncogenes, transcription factors (e.g. MYC, HIF1, NRF2) and inactivation of tumor suppressors, such as TP53, allow invasiveness and chemoresistance, in part, by regulating mitochondrial function and metabolism as well as by controling the outcome of ROS generation. Metabolic stress, immune surveillance and chemotherapy act as a selective pressure that allows only the survival of cells with specic features, driving cancer cells towards a highly glycolytic, apoptosis-incompetent and invasive phenotype. Given the complexity in the metabolic alterations of cancer cells mediated largely through alterations in mitochondrial function, further research is required to identify more efficient strategies

Ribas et al. Clin Trans Med (2016) 5:22

Page 17 of 24

for cancer treatment involving the use of small molecules targeting mitochondrial metabolism.

Abbreviations

ROS: reactive oxygen species; OXPHOS: oxidative phosphorylation; HMG CoAR: 3hydroxy3methylglutarylCoA reductase; HCC: hepatocellular carcinoma; TCGA: cancer genome atlas; mtDNA: mitochondrial DNA; MIM: mitochondrial inner membrane; MOM: mitochondrial outer membrane; ALR: augmenter of liver regeneration; ETC: electron transport chain; m: mitochondrial transmembrane potential; TCA: tricarboxylic acid cycle; ACLY:

ATP citrate lyase; mGSH: mitochondrial glutathione; H2O2: hydrogen peroxide; SOD: superoxide dismutases; 2OG: 2oxoglutrarate; GPX: glutathione peroxidase; mGSSG: mitochondrial oxidized glutathione; Prx/Trx: peroxire doxin/thioredoxin; MOMP: mitochondrial outer membrane permeabilization; IMS: mitochondrial intermembrane space; BOK: BCL2 ovarian killer; MPT: mitochondrial permeability transition; VDAC: voltagedependent anion channel; ANT: adenine nucleotide translocase; TSPO: translocator protein; RIPK1: receptorinteracting serine/threonineprotein kinase 1; MLKL: mixed lineage kinase domainlike protein; IPP: isopentenyl pyrophosphate; DMAPP: dimethyl allyl pyrophosphate; GPP: geranyl pyrophosphate; FFP: farnesyl pyrophosphate; GGPP: geranyl geranyl pyrophosphate; SS: squalene syn thase; ER: endoplasmic reticulum; ABCA1: ATP binding cassette transporter A1; StARD1: steroidogenic acute regulatory domain 1; PET: positron emission tomography; PDK1: pyruvate dehydrogenase kinase; ARK5: AMPKrelated protein kinase 5; PGC1: peroxisome proliferatoractivated receptor gamma coactivator 1 alpha; GLS2: glutaminase 2; HIF1: hypoxiainducible factor1 alpha; PHD: HIFprolyhydroxylase; pVHL: Von HippelLandau ubiquitin ligase; LDHA: lactate dehydrogenase A; MCT4: monocarboxylate transporter 4; COX42: cytochrome c oxidase subunit 42; BNIP3: BCL2/adenovirus E1B 19kDa interacting protein 3; 2OG: 2oxoglutarate; FIH: factor inhibiting HIF1; SDH: succinate dehydrogenase; IDH: isocitrate dehydrogenase; NAC: Nacetyl

Lcysteine; NRF2: NFE2related factor; KEAP1: Kelchlike ECHassociated protein 1; BHA: butylated hydroxyanisole; CDDO: 2cyano3,12dioxooleana 1,9diene28oic acid; FH: fumarate hydratase; 2OGC: 2oxoglutarate carrier; DRP1: dynaminrelated protein 1; BPTES: bis2(5phenylacetamido1,3,4thi adiazol2yl)ethyl sulde; DON: 6diazo5oxoLnorleucine; GDH: glutamate dehydrogenase; EGCG: epigallocatechin3gallate; LDH: lactate dehydroge nase; AMPK: AMPactivated Kinase; PEITC: phenethyl isothiocyanate; BSO: buthionine sulfoximine; FTase: farnesyltransferase; FTI: farnesyltransferase inhibitors; GGTI: geranyl geranyl transferase inhibitor.

Authors contributions

VR, CGR and JCFC participated in the design of the study, revised literature, and discussed data jointly. VR, CGR and JCFC drafted Figures and the writing of the text. All authors read and approved the nal manuscript.

Author details

1 Department of Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), Consejo Superior Investigaciones Cienticas (CSIC), Barcelona, Spain. 2 Liver UnitHospital Clnic, Centre Esther Koplowitz, IDIBAPS, CIBEREHD, Planta Cuarta, C/Rossell 149, Barcelona 08036, Spain. 3 Research Center for ALPD and Cirrhosis, Ckeck School of Medicine, University of South ern California, Los Angeles, CA, USA.

Acknowledgements

Vicent Ribas is recipient of an IDIBAPS Postdoctoral FellowshipBIOTRACK, supported by the European Communitys Seventh Framework Programme (EC FP7/20072013) under the Grant agreement number 229673 and the Spanish Ministry of Economy and Competitiveness (MINECO) through the Grant COFUND201340261. The work was supported by CIBEREHD, Fundaci la Marat de TV3 and Grants PI11/0325 (META) from the Instituto Salud Carlos III and Grants, SAF201123031, SAF201234831, SAF201457674R and SAF2015 69944R from Plan Nacional de I+D, Spain; Fundacin Mutua Madrilea and

the center Grant P50AA11999 (Research Center for Liver and Pancreatic Diseases, NIAAA/NIH).

Competing interests

The authors declare that they have no competing interests.

Received: 12 April 2016 Accepted: 26 June 2016

References

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next genera tion. Cell 144(5):646674. doi:http://dx.doi.org/10.1016/j.cell.2011.02.013

Web End =10.1016/j.cell.2011.02.013

2. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC et al (2009) Anti and protumor functions of autophagy. Biochim Biophys Acta 1793(9):15241532. doi:http://dx.doi.org/10.1016/j.bbamcr.2009.01.006

Web End =10.1016/j.bbamcr.2009.01.006

3. Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E et al (2010) Mitochondrial gateways to cancer. Mol Aspects Med 31(1):120. doi:http://dx.doi.org/10.1016/j.mam.2009.08.002

Web End =10.1016/j.mam.2009.08.002

4. Raimundo N (2014) Mitochondrial pathology: stress signals from the energy factory. Trend Mol Med. doi:http://dx.doi.org/10.1016/j.molmed.2014.01.005

Web End =10.1016/j.molmed.2014.01.005

5. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA et al (2008) LXR signaling couples sterol metabolism to proliferationin the acquired immune response. Cell 134(1):97111. doi:http://dx.doi.org/10.1016/j.cell.2008.04.052

Web End =10.1016/j. http://dx.doi.org/10.1016/j.cell.2008.04.052

Web End =cell.2008.04.052

6. Lo Sasso G, Celli N, Caboni M, Murzilli S, Salvatore L, Morgano Aet al (2010) Downregulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. Hepatology 51(4):13341344. doi:http://dx.doi.org/10.1002/hep.23436

Web End =10.1002/hep.23436

7. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA et al (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 107(34):1505115056. doi:http://dx.doi.org/10.1073/pnas.0910258107

Web End =10.1073/pnas.0910258107

8. Dang CV (2012) Links between metabolism and cancer. Gene Dev 26(9):877890. doi:http://dx.doi.org/10.1101/gad.189365.112

Web End =10.1101/gad.189365.112

9. Borena W, Strohmaier S, Lukanova A, Bjorge T, Lindkvist B, Hallmans G et al (2012) Metabolic risk factors and primary liver cancer in a prospec tive study of 578,700 adults. Int J Cancer 131(1):193200. doi:http://dx.doi.org/10.1002/ijc.26338

Web End =10.1002/ http://dx.doi.org/10.1002/ijc.26338

Web End =ijc.26338

10. Singh S, Singh PP (2014) Statins for prevention of hepatocellular cancer: one step closer? Hepatology 59(2):724726. doi:http://dx.doi.org/10.1002/hep.26614

Web End =10.1002/hep.26614

11. StryjkowskaGora A, KarczmarekBorowska B, Gora T, Krawczak K (2015) Statins and cancers. Contemp Oncol. 19(3):167175. doi:http://dx.doi.org/10.5114/wo.2014.44294

Web End =10.5114/ http://dx.doi.org/10.5114/wo.2014.44294

Web End =wo.2014.44294

12. Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J (2014) Identication of anticancer drugs for hepatocellular carcinoma through personalized genomescale metabolic modeling. Mol Syst Biol. 10:721. doi:http://dx.doi.org/10.1002/msb.145122

Web End =10.1002/msb.145122

13. Cao Z, FanMinogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Qet al (2011) MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMGCoA reductase. Cancer Res 71(6):22862297. doi:http://dx.doi.org/10.1158/0008-5472.CAN-10-3367

Web End =10.1158/00085472.CAN103367

14. Mansourian PG, Yoneda M, Krishna Rao M, Martinez FJ, Thomas E, Schi ER (2014) Eects of statins on the risk of hepatocellular carcinoma. Gastroenterol & Hepatol. 10(7):417426

15. Cancer Genome Atlas Research, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA et al (2013) The cancer genome atlas pancan cer analysis project. Nat Genet 45(10):11131120. doi:http://dx.doi.org/10.1038/ng.2764

Web End =10.1038/ng.2764

16. Kuzu OF, Noory MA, Robertson GP (2016) The role of cholesterol in can cer. Cancer Res 76(8):20632070. doi:http://dx.doi.org/10.1158/0008-5472.CAN-15-2613

Web End =10.1158/00085472.CAN152613

17. Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basanez Get al (2008) Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 68(13):52465256. doi:http://dx.doi.org/10.1158/0008-5472.CAN-07-6161

Web End =10.1158/00085472.CAN076161

18. LuckenArdjomande S, Montessuit S, Martinou JC (2008) Bax activation and stressinduced apoptosis delayed by the accumulation of choles terol in mitochondrial membranes. Cell Death Dier 15(3):484493. doi:http://dx.doi.org/10.1038/sj.cdd.4402280

Web End =10.1038/sj.cdd.4402280

19. Mishra P, Chan DC (2014) Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol 15(10):634646. doi:http://dx.doi.org/10.1038/nrm3877

Web End =10.1038/nrm3877

20. Sukhorukov VM, MeyerHermann M (2015) Structural Heterogeneity of mitochondria induced by the microtubule cytoskeleton. Sci Rep. 5:13924. doi:http://dx.doi.org/10.1038/srep13924

Web End =10.1038/srep13924

Ribas et al. Clin Trans Med (2016) 5:22

Page 18 of 24

21. Patergnani S, Missiroli S, Marchi S, Giorgi C (2015) Mitochondriaassoci ated endoplasmic reticulum membranes microenvironment: targeting autophagic and apoptotic pathways in cancer therapy. Front Oncol. 5:173. doi:http://dx.doi.org/10.3389/fonc.2015.00173

Web End =10.3389/fonc.2015.00173

22. Ghosh S, Singh KK, Sengupta S, Scaria V (2015) Mitoepigenetics: the dierent shades of grey. Mitochondrion 25:6066. doi:http://dx.doi.org/10.1016/j.mito.2015.09.003

Web End =10.1016/j. http://dx.doi.org/10.1016/j.mito.2015.09.003

Web End =mito.2015.09.003

23. Chacinska A, Pfannschmidt S, Wiedemann N, Kozjak V, Sanjuan Szklarz LK, SchulzeSpecking A et al (2004) Essential role of Mia40 in import and assembly of mitochondrial intermembrane space proteins. EMBO J 23(19):37353746. doi:http://dx.doi.org/10.1038/sj.emboj.7600389

Web End =10.1038/sj.emboj.7600389

24. Fischer M, Horn S, Belkacemi A, Kojer K, Petrungaro C, Habich M et al (2013) Protein import and oxidative folding in the mitochondrial inter membrane space of intact mammalian cells. Mol Biol Cell 24(14):2160 2170. doi:http://dx.doi.org/10.1091/mbc.E12-12-0862

Web End =10.1091/mbc.E12120862

25. Gandhi CR, Chaillet JR, Nalesnik MA, Kumar S, Dangi A, Demetris AJ et al (2014) Liverspecic deletion of augmenter of liver regenera tion accelerates development of steatohepatitis and hepatocellular carcinoma in mice. Gastroenterology 148(2):379391. doi:http://dx.doi.org/10.1053/j.gastro.2014.10.008

Web End =10.1053/j. http://dx.doi.org/10.1053/j.gastro.2014.10.008

Web End =gastro.2014.10.008

26. Maehara Y, FernandezCheca JC (2015) Augmenter of liver regenera tion links mitochondrial function to steatohepatitis and hepatocel lular carcinoma. Gastroenterology 148(2):285288. doi:http://dx.doi.org/10.1053/j.gastro.2014.12.013

Web End =10.1053/j. http://dx.doi.org/10.1053/j.gastro.2014.12.013

Web End =gastro.2014.12.013

27. Calvo SE, Clauser KR, Mootha VK (2015) MitoCarta 2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res. doi:http://dx.doi.org/10.1093/nar/gkv1003

Web End =10.1093/nar/gkv1003

28. Venditti P, Di Stefano L, Di Meo S (2013) Mitochondrial metabolism of reactive oxygen species. Mitochondrion 13(2):7182. doi:http://dx.doi.org/10.1016/j.mito.2013.01.008

Web End =10.1016/j. http://dx.doi.org/10.1016/j.mito.2013.01.008

Web End =mito.2013.01.008

29. Sun F, Zhou Q, Pang X, Xu Y, Rao Z (2013) Revealing various coupling of electron transfer and proton pumping in mitochondrial res piratory chain. Curr Opin Struct Biol 23(4):526538. doi:http://dx.doi.org/10.1016/j.sbi.2013.06.013

Web End =10.1016/j. http://dx.doi.org/10.1016/j.sbi.2013.06.013

Web End =sbi.2013.06.013

30. Kulawiak B, Hopker J, Gebert M, Guiard B, Wiedemann N, Gebert N (2013) The mitochondrial protein import machinery has multiple con nections to the respiratory chain. Biochim Biophys Acta 1827(5):612 626. doi:http://dx.doi.org/10.1016/j.bbabio.2012.12.004

Web End =10.1016/j.bbabio.2012.12.004

31. Cheng Z, Ristow M (2013) Mitochondria and metabolic homeostasis. Antioxid Redox Signal 19(3):240242. doi:http://dx.doi.org/10.1089/ars.2013.5255

Web End =10.1089/ars.2013.5255 32. Hammerman PS, Fox CJ, Thompson CB (2004) Beginnings of a signal transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci 29(11):586592. doi:http://dx.doi.org/10.1016/j.tibs.2004.09.008

Web End =10.1016/j.tibs.2004.09.008

33. Renault TT, Chipuk JE (2013) Interorganellar communication with mitochondria regulates both the intrinsic and extrinsic pathways of apoptosis. Commun Integr Biol. 6(2):e22872. doi:http://dx.doi.org/10.4161/cib.22872

Web End =10.4161/cib.22872

34. Arnould T, Michel S, Renard P (2015) Mitochondria retrograde signaling and the UPR mt: where are we in mammals? Int J Mol Sci 16(8):18224 18251. doi:http://dx.doi.org/10.3390/ijms160818224

Web End =10.3390/ijms160818224

35. Guha M, Avadhani NG (2013) Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mito chondrion 13(6):577591. doi:http://dx.doi.org/10.1016/j.mito.2013.08.007

Web End =10.1016/j.mito.2013.08.007

36. Brand MD (2010) The sites and topology of mitochondrial super oxide production. Exp Gerontol 45(78):466472. doi:http://dx.doi.org/10.1016/j.exger.2010.01.003

Web End =10.1016/j. http://dx.doi.org/10.1016/j.exger.2010.01.003

Web End =exger.2010.01.003

37. Quinlan CL, Perevoschikova IV, Goncalves RL, HeyMogensen M, Brand MD (2013) The determination and analysis of sitespecic rates of mitochondrial reactive oxygen species production. Methods Enzymol 526:189217. doi:http://dx.doi.org/10.1016/B978-0-12-405883-5.00012-0

Web End =10.1016/B9780124058835.000120

38. Quinlan CL, Perevoshchikova IV, HeyMogensen M, Orr AL, Brand MD (2013) Sites of reactive oxygen species generation by mitochondria oxidizing dierent substrates. Redox Biol. 1:304312. doi:http://dx.doi.org/10.1016/j.redox.2013.04.005

Web End =10.1016/j. http://dx.doi.org/10.1016/j.redox.2013.04.005

Web End =redox.2013.04.005

39. Ribas V, GarciaRuiz C, FernandezCheca JC (2014) Glutathione and mitochondria. Front Pharmacol doi:http://dx.doi.org/10.3389/fphar.2014.00151

Web End =10.3389/fphar.2014.00151 40. Cadenas E, Davies KJ (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radical Biol Med 29(34):222230

41. Mari M, Colell A, Morales A, von Montfort C, GarciaRuiz C, Fernandez Checa JC (2010) Redox control of liver function in health and disease. Antioxid Redox Signal 12(11):12951331. doi:http://dx.doi.org/10.1089/ars.2009.2634

Web End =10.1089/ars.2009.2634

42. Sena LA, Chandel NS (2012) Physiological roles of mitochondrial reactive oxygen species. Mol Cell 48(2):158167. doi:http://dx.doi.org/10.1016/j.molcel.2012.09.025

Web End =10.1016/j. http://dx.doi.org/10.1016/j.molcel.2012.09.025

Web End =molcel.2012.09.025

43. Mari M, Morales A, Colell A, GarciaRuiz C, Kaplowitz N, Fernandez Checa JC (2013) Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta 1830(5):33173328. doi:http://dx.doi.org/10.1016/j.bbagen.2012.10.018

Web End =10.1016/j. http://dx.doi.org/10.1016/j.bbagen.2012.10.018

Web End =bbagen.2012.10.018

44. McCommis KS, McGee AM, Laughlin MH, Bowles DK, Baines CP (2011) Hypercholesterolemia increases mitochondrial oxidative stress and enhances the MPT response in the porcine myocardium: benecial eects of chronic exercise. Am J Physiol Regul Integr Comp Physiol 301(5):R1250R1258. doi:http://dx.doi.org/10.1152/ajpregu.00841.2010

Web End =10.1152/ajpregu.00841.2010

45. Sies H (2014) Role of metabolic H2O2 generation: redox signaling and oxidative stress. J Biol Chem 289(13):87358741. doi:http://dx.doi.org/10.1074/jbc.R113.544635

Web End =10.1074/jbc.

http://dx.doi.org/10.1074/jbc.R113.544635

Web End =R113.544635 46. Kil IS, Ryu KW, Lee SK, Kim JY, Chu SY, Kim JH et al (2015) Circadian oscillation of sulredoxin in the mitochondria. Mol Cell 59(4):651663. doi:http://dx.doi.org/10.1016/j.molcel.2015.06.031

Web End =10.1016/j.molcel.2015.06.031

47. Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9(3):231241. doi:http://dx.doi.org/10.1038/nrm2312

Web End =10.1038/ http://dx.doi.org/10.1038/nrm2312

Web End =nrm2312

48. LiM X, Dewson G (2015) Mitochondria and apoptosis: emerging con cepts. F1000Prime Rep 7:42. doi:http://dx.doi.org/10.12703/P7-42

Web End =10.12703/P742

49. Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87(1):99163. doi:http://dx.doi.org/10.1152/physrev.00013.2006

Web End =10.1152/ http://dx.doi.org/10.1152/physrev.00013.2006

Web End =physrev.00013.2006

50. Martinou JC, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2(1):6367. doi:http://dx.doi.org/10.1038/35048069

Web End =10.1038/35048069

51. Westphal D, Kluck RM, Dewson G (2014) Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Dier 21(2):196205. doi:http://dx.doi.org/10.1038/cdd.2013.139

Web End =10.1038/cdd.2013.139

52. Llambi F, Wang YM, Victor B, Yang M, Schneider DM, Gingras S et al (2016) BOK Is a noncanonical BCL2 family eector of apoptosis regu lated by ERassociated degradation. Cell. doi:http://dx.doi.org/10.1016/j.cell.2016.02.026

Web End =10.1016/j.cell.2016.02.026

53. Youle RJ, Strasser A (2008) The BCL2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):4759. doi:http://dx.doi.org/10.1038/nrm2308

Web End =10.1038/ http://dx.doi.org/10.1038/nrm2308

Web End =nrm2308

54. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al (1997) Cytochrome c and dATPdependent formation of Apaf1/ caspase9 complex initiates an apoptotic protease cascade. Cell 91(4):479489

55. Li LY, Luo X, Wang X (2001) Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412(6842):9599. doi:http://dx.doi.org/10.1038/35083620

Web End =10.1038/35083620

56. MunozPinedo C, GuioCarrion A, Goldstein JC, Fitzgerald P, New meyer DD, Green DR (2006) Dierent mitochondrial intermembrane space proteins are released during apoptosis in a manner that is coordinately initiated but can vary in duration. Proc Natl Acad Sci USA 103(31):1157311578. doi:http://dx.doi.org/10.1073/pnas.0603007103

Web End =10.1073/pnas.0603007103

57. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome cdependent caspase activation by elimi nating IAP inhibition. Cell 102(1):3342

58. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandena beele P (2004) Toxic proteins released from mitochondria in cell death. Oncogene 23(16):28612874. doi:http://dx.doi.org/10.1038/sj.onc.1207523

Web End =10.1038/sj.onc.1207523

59. Modjtahedi N, Giordanetto F, Madeo F, Kroemer G (2006) Apoptosis inducing factor: vital and lethal. Trend Cell Biol 16(5):264272. doi:http://dx.doi.org/10.1016/j.tcb.2006.03.008

Web End =10.1016/j.tcb.2006.03.008

60. Lee HJ, Pyo JO, Oh Y, Kim HJ, Hong SH, Jeon YJ et al (2007) AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase10. Nat Cell Biol 9(11):13031310. doi:http://dx.doi.org/10.1038/ncb1650

Web End =10.1038/ncb1650

61. Gonzalvez F, Gottlieb E (2007) Cardiolipin: setting the beat of apoptosis. Apoptosis Int J Program Cell Death 12(5):877885. doi:http://dx.doi.org/10.1007/s10495-007-0718-8

Web End =10.1007/ http://dx.doi.org/10.1007/s10495-007-0718-8

Web End =s1049500707188

62. Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AAet al (2005) Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 1(4):223232. doi:http://dx.doi.org/10.1038/nchembio727

Web End =10.1038/nchembio727

63. Mari M, Colell A, Morales A, Caballero F, Moles A, Fernandez Aet al (2008) Mechanism of mitochondrial glutathionedependent

Ribas et al. Clin Trans Med (2016) 5:22

Page 19 of 24

hepatocellular susceptibility to TNF despite NFkappaB activation. Gastroenterology 134(5):15071520. doi:http://dx.doi.org/10.1053/j.gastro.2008.01.073

Web End =10.1053/j.gastro.2008.01.073 64. Mari M, Morales A, Colell A, GarciaRuiz C, FernandezCheca JC (2009) Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11(11):26852700. doi:http://dx.doi.org/10.1089/ARS.2009.2695

Web End =10.1089/ARS.2009.2695

65. Montero J, Mari M, Colell A, Morales A, Basanez G, GarciaRuiz C et al (2010) Cholesterol and peroxidized cardiolipin in mitochondrial mem brane properties, permeabilization and cell death. Biochim Biophys Acta 1797(67):12171224. doi:http://dx.doi.org/10.1016/j.bbabio.2010.02.010

Web End =10.1016/j.bbabio.2010.02.010

66. Landeta O, Landajuela A, Gil D, Taneva S, Di Primo C, Sot B et al (2011) Reconstitution of proapoptotic BAK function in liposomes reveals a dual role for mitochondrial lipids in the BAKdriven membrane per meabilization process. J Biol Chem 286(10):82138230. doi:http://dx.doi.org/10.1074/jbc.M110.165852

Web End =10.1074/jbc. http://dx.doi.org/10.1074/jbc.M110.165852

Web End =M110.165852

67. Frisch SM, Ruoslahti E (1997) Integrins and anoikis. Curr Opin Cell Biol 9(5):701706

68. Gilmore AP (2005) Anoikis. Cell Death Dier 12(Suppl 2):14731477. doi:http://dx.doi.org/10.1038/sj.cdd.4401723

Web End =10.1038/sj.cdd.4401723

69. Schafer ZT, Grassian AR, Song L, Jiang Z, GerhartHines Z, Irie HY et al (2009) Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461(7260):109113. doi:http://dx.doi.org/10.1038/nature08268

Web End =10.1038/ http://dx.doi.org/10.1038/nature08268

Web End =nature08268

70. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan Met al (2012) Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol 32(10):18931907. doi:http://dx.doi.org/10.1128/MCB.06248-11

Web End =10.1128/MCB.0624811

71. Kamarajugadda S, Cai Q, Chen H, Nayak S, Zhu J, He M et al (2013) Man ganese superoxide dismutase promotes anoikis resistance and tumor metastasis. Cell Death Dis 4:e504. doi:http://dx.doi.org/10.1038/cddis.2013.20

Web End =10.1038/cddis.2013.20

72. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA et al (2005) Loss of cyclophilin D reveals a critical role for mitochon drial permeability transition in cell death. Nature 434(7033):658662. doi:http://dx.doi.org/10.1038/nature03434

Web End =10.1038/nature03434

73. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, YamagataH et al (2005) Cyclophilin Ddependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434(7033):652658. doi:http://dx.doi.org/10.1038/nature03317

Web End =10.1038/nature03317

74. GutierrezAguilar M, Baines CP (2015) Structural mechanisms of cyclo philin Ddependent control of the mitochondrial permeability transi tion pore. Biochim Biophys Acta 1850(10):20412047. doi:http://dx.doi.org/10.1016/j.bbagen.2014.11.009

Web End =10.1016/j. http://dx.doi.org/10.1016/j.bbagen.2014.11.009

Web End =bbagen.2014.11.009

75. McCommis KS, Baines CP (2012) The role of VDAC in cell death: friend or foe? Biochim Biophys Acta 1818(6):14441450. doi:http://dx.doi.org/10.1016/j.bbamem.2011.10.025

Web End =10.1016/j. http://dx.doi.org/10.1016/j.bbamem.2011.10.025

Web End =bbamem.2011.10.025

76. Sileikyte J, BlachlyDyson E, Sewell R, Carpi A, Menabo R, Di Lisa F et al (2014) Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (TSPO). J Biol Chem. doi:http://dx.doi.org/10.1074/jbc.M114.549634

Web End =10.1074/jbc.M114.549634

77. Christoerson DE, Yuan J (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22(2):263268. doi:http://dx.doi.org/10.1016/j.ceb.2009.12.003

Web End =10.1016/j.ceb.2009.12.003

78. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G (2010) Molecu lar mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11(10):700714. doi:http://dx.doi.org/10.1038/nrm2970

Web End =10.1038/nrm2970

79. Ardestani S, Deskins DL, Young PP (2013) Membrane TNFalphaacti vated programmed necrosis is mediated by ceramideinduced reactive oxygen species. J Mol Signal 8(1):12. doi:http://dx.doi.org/10.1186/1750-2187-8-12

Web End =10.1186/17502187812

80. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343(6257):425430. doi:http://dx.doi.org/10.1038/343425a0

Web End =10.1038/343425a0

81. Edwards PA, Ericsson J (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Ann Rev Biochem 68:157185. doi:http://dx.doi.org/10.1146/annurev.biochem.68.1.157

Web End =10.1146/annurev.biochem.68.1.157

82. Brusselmans K, Timmermans L, Van de Sande T, Van Veldhoven PP, Guan G, Shechter I et al (2007) Squalene synthase, a determinant of Raft associated cholesterol and modulator of cancer cell proliferation. J Biol Chem 282(26):1877718785. doi:http://dx.doi.org/10.1074/jbc.M611763200

Web End =10.1074/jbc.M611763200

83. Sever N, Yang T, Brown MS, Goldstein JL, DeBoseBoyd RA (2003) Accelerated degradation of HMG CoA reductase mediated by binding of insig1 to its sterolsensing domain. Mol Cell 11(1):2533

84. Nguyen AD, McDonald JG, Bruick RK, DeBoseBoyd RA (2007) Hypoxia stimulates degradation of 3hydroxy3methylglutarylcoenzyme A reductase through accumulation of lanosterol and hypoxiainducible

factormediated induction of insigs. J Biol Chem 282(37):2743627446. doi:http://dx.doi.org/10.1074/jbc.M704976200

Web End =10.1074/jbc.M704976200 85. GarciaRuiz C, Mari M, Colell A, Morales A, Caballero F, Montero J et al (2009) Mitochondrial cholesterol in health and disease. Histol Histo pathol 24(1):117132

86. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D et al (2011) An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP1/LDLRdependent pathway. Cancer discovery. 1(5):442456. doi:http://dx.doi.org/10.1158/2159-8290.CD-11-0102

Web End =10.1158/21598290.CD110102

87. Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D et al (2015) Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol 35(Suppl):S199S223. doi:http://dx.doi.org/10.1016/j.semcancer.2015.02.007

Web End =10.1016/j.semcancer.2015.02.007

88. Maxeld FR, Tabas I (2005) Role of cholesterol and lipid organization in disease. Nature 438(7068):612621. doi:http://dx.doi.org/10.1038/nature04399

Web End =10.1038/nature04399

89. Crain RC, Clark RW, Harvey BE (1983) Role of lipid transfer proteins in the abnormal lipid content of Morris hepatoma mitochondria and microsomes. Cancer Res 43(7):31973202

90. Feo F, Canuto RA, Garcea R, Gabriel L (1975) Eect of cholesterol content on some physical and functional properties of mitochon dria isolated from adult rat liver, fetal liver, cholesterolenriched liver and hepatomas AH130, 3924A and 5123. Biochim Biophys Acta 413(1):116134

91. Miller WL (2013) Steroid hormone synthesis in mitochondria. Mol Cell Endocrinol 379(12):6273. doi:http://dx.doi.org/10.1016/j.mce.2013.04.014

Web End =10.1016/j.mce.2013.04.014

92. Caron KM, Soo SC, Wetsel WC, Stocco DM, Clark BJ, Parker KL (1997) Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci USA 94(21):1154011545

93. Kishida T, Kostetskii I, Zhang Z, Martinez F, Liu P, Walkley SU et al (2004) Targeted mutation of the MLN64 START domain causes only modest alterations in cellular sterol metabolism. J Biol Chem 279(18):19276 19285. doi:http://dx.doi.org/10.1074/jbc.M400717200

Web End =10.1074/jbc.M400717200

94. Charman M, Kennedy BE, Osborne N, Karten B (2010) MLN64 mediates egress of cholesterol from endosomes to mitochondria in the absence of functional NiemannPick Type C1 protein. J Lipid Res 51(5):1023 1034. doi:http://dx.doi.org/10.1194/jlr.M002345

Web End =10.1194/jlr.M002345

95. Smith B, Land H (2012) Anticancer activity of the cholesterol exporter ABCA1 gene. Cell reports. 2(3):580590. doi:http://dx.doi.org/10.1016/j.celrep.2012.08.011

Web End =10.1016/j.celrep.2012.08.011

96. Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269270

97. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancers Achil les heel. Cancer Cell 13(6):472482. doi:http://dx.doi.org/10.1016/j.ccr.2008.05.005

Web End =10.1016/j.ccr.2008.05.005

98. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519530

99. Alam MM, Lal S, FitzGerald KE, Zhang L (2016) A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamen tal roles in the development and progression of diverse tumors. Clin Trans Med 5(1):114. doi:http://dx.doi.org/10.1186/s40169-016-0082-9

Web End =10.1186/s4016901600829

100. Manko DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AMet al (2007) Tumorspecic positron emission tomography imaging in patients: [18F] uorodeoxyglucose and beyond. Clin Cancer Res 13(12):34603469. doi:http://dx.doi.org/10.1158/1078-0432.CCR-07-0074

Web End =10.1158/10780432.CCR070074

101. Levine AJ, PuzioKuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330(6009):13401344. doi:http://dx.doi.org/10.1126/science.1193494

Web End =10.1126/science.1193494

102. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21(3):297308. doi:http://dx.doi.org/10.1016/j.ccr.2012.02.014

Web End =10.1016/j.ccr.2012.02.014

103. Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Ann Rev Cell Dev Biol 27:441464. doi:http://dx.doi.org/10.1146/annurev-cellbio-092910-154237

Web End =10.1146/annurevcellbio092910154237

104. VanderHeiden MG, Cantley LC, Thompson CB (2009) Understanding the warburg eect: the metabolic requirements of cell proliferation. Science 324(5930):10291033. doi:http://dx.doi.org/10.1126/science.1160809

Web End =10.1126/science.1160809

105. Vincent M (2012) Cancer: a derepression of a default survival program common to all cells?: a lifehistory perspective on the nature of cancer. BioEssays News Rev Mol Cell Develop Biol 34(1):7282. doi:http://dx.doi.org/10.1002/bies.201100049

Web End =10.1002/ http://dx.doi.org/10.1002/bies.201100049

Web End =bies.201100049

106. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeier HK et al (2008) Myc regulates a transcriptional program that stimulates

Ribas et al. Clin Trans Med (2016) 5:22

Page 20 of 24

mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105(48):1878218787. doi:http://dx.doi.org/10.1073/pnas.0810199105

Web End =10.1073/pnas.0810199105 107. Gogvadze V, Zhivotovsky B, Orrenius S (2010) The warburg eect and mitochondrial stability in cancer cells. Mol Aspects Med 31(1):6074. doi:http://dx.doi.org/10.1016/j.mam.2009.12.004

Web End =10.1016/j.mam.2009.12.004 108. KsiezakowskaLakoma K, Zyla M, Wilczynski JR (2014) Mitochondrial dysfunction in cancer. Menopause Rev 13(2):136144. doi:http://dx.doi.org/10.5114/pm.2014.42717

Web End =10.5114/ http://dx.doi.org/10.5114/pm.2014.42717

Web End =pm.2014.42717 109. Wahlstrom T, Henriksson MA (2015) Impact of MYC in regulationof tumor cell metabolism. Biochim Biophys Acta 1849(5):563569. doi:http://dx.doi.org/10.1016/j.bbagrm.2014.07.004

Web End =10.1016/j.bbagrm.2014.07.004 110. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, ODonnell KA et al (2005)

Myc stimulates nuclearly encoded mitochondrial genes and mito chondrial biogenesis. Mol Cell Biol 25(14):62256234. doi:http://dx.doi.org/10.1128/MCB.25.14.6225-6234.2005

Web End =10.1128/ http://dx.doi.org/10.1128/MCB.25.14.6225-6234.2005

Web End =MCB.25.14.62256234.2005 111. Kim J, Lee JH, Iyer VR (2008) Global identication of Myc target genes reveals its direct role in mitochondrial biogenesis and its Ebox usage in vivo. PLoS One 3(3):e1798. doi:http://dx.doi.org/10.1371/journal.pone.0001798

Web End =10.1371/journal.pone.0001798 112. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR et al (2012)

Deregulated MYC expression induces dependence upon AMPKrelated kinase 5. Nature 483(7391):608612. doi:http://dx.doi.org/10.1038/nature10927

Web End =10.1038/nature10927 113. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al (2012) Glucose independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110121. doi:http://dx.doi.org/10.1016/j.cmet.2011.12.009

Web End =10.1016/j. http://dx.doi.org/10.1016/j.cmet.2011.12.009

Web End =cmet.2011.12.009 114. Liu YC, Li F, Handler J, Huang CR, Xiang Y, Neretti N et al (2008) Global regulation of nucleotide biosynthetic genes by cMyc. PLoS One 3(7):e2722. doi:http://dx.doi.org/10.1371/journal.pone.0002722

Web End =10.1371/journal.pone.0002722 115. Viale A, Corti D, Draetta GF (2015) Tumors and mitochondrial respira tion: a neglected connection. Cancer Res. doi:http://dx.doi.org/10.1158/0008-5472.CAN-15-0491

Web End =10.1158/00085472. http://dx.doi.org/10.1158/0008-5472.CAN-15-0491

Web End =CAN150491 116. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin

M et al (2013) BCL2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12(3):329341. doi:http://dx.doi.org/10.1016/j.stem.2012.12.013

Web End =10.1016/j.stem.2012.12.013 117. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher

D et al (2013) Overcoming intrinsic multidrug resistance in mela noma by blocking the mitochondrial respiratory chain of slow cycling JARID1B(high) cells. Cancer Cell 23(6):811825. doi:http://dx.doi.org/10.1016/j.ccr.2013.05.003

Web End =10.1016/j. http://dx.doi.org/10.1016/j.ccr.2013.05.003

Web End =ccr.2013.05.003 118. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M et al

(2014) Oncogene ablationresistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628632. doi:http://dx.doi.org/10.1038/nature13611

Web End =10.1038/ http://dx.doi.org/10.1038/nature13611

Web End =nature13611 119. Sancho P, BurgosRamos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals

M et al (2015) MYC/PGC1alpha balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 22(4):590605. doi:http://dx.doi.org/10.1016/j.cmet.2015.08.015

Web End =10.1016/j.cmet.2015.08.015 120. Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z et al

(2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20(5):674688. doi:http://dx.doi.org/10.1016/j.ccr.2011.10.015

Web End =10.1016/j.ccr.2011.10.015 121. Wolf DA (2014) Is reliance on mitochondrial respiration a chink inthe armor of therapyresistant cancer? Cancer Cell 26(6):788795. doi:http://dx.doi.org/10.1016/j.ccell.2014.10.001

Web End =10.1016/j.ccell.2014.10.001 122. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova

O et al (2006) p53 regulates mitochondrial respiration. Science 312(5780):16501653. doi:http://dx.doi.org/10.1126/science.1126863

Web End =10.1126/science.1126863 123. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al

(2006) TIGAR, a p53inducible regulator of glycolysis and apoptosis. Cell 126(1):107120. doi:http://dx.doi.org/10.1016/j.cell.2006.05.036

Web End =10.1016/j.cell.2006.05.036 124. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Meta bolic regulation by p53 family members. Cell Metab 18(5):617633. doi:http://dx.doi.org/10.1016/j.cmet.2013.06.019

Web End =10.1016/j.cmet.2013.06.019 125. Semenza GL (2003) Targeting HIF1 for cancer therapy. Nat Rev Cancer

3(10):721732. doi:http://dx.doi.org/10.1038/nrc1187

Web End =10.1038/nrc1187 126. Melillo G (2006) Inhibiting hypoxiainducible factor 1 for cancer therapy. Mol Cancer Res 4(9):601605. doi:http://dx.doi.org/10.1158/1541-7786.MCR-06-0235

Web End =10.1158/15417786.MCR060235 127. Brocato J, Chervona Y, Costa M (2014) Molecular responses to hypoxia inducible factor 1alpha and beyond. Mol Pharmacol 85(5):651657. doi:http://dx.doi.org/10.1124/mol.113.089623

Web End =10.1124/mol.113.089623

128. Kaelin WG Jr, Ratclie PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30(4):393402. doi:http://dx.doi.org/10.1016/j.molcel.2008.04.009

Web End =10.1016/j.molcel.2008.04.009

129. Semenza GL (2011) Regulation of metabolism by hypoxiainducible fac tor 1. Quant Biol. 76:347353. doi:http://dx.doi.org/10.1101/sqb.2011.76.010678

Web End =10.1101/sqb.2011.76.010678

130. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL (2007)

HIF1 regulates cytochrome oxidase subunits to optimize efficiencyof respiration in hypoxic cells. Cell 129(1):111122. doi:http://dx.doi.org/10.1016/j.cell.2007.01.047

Web End =10.1016/j. http://dx.doi.org/10.1016/j.cell.2007.01.047

Web End =cell.2007.01.047 131. Lim JH, Luo C, Vazquez F, Puigserver P (2014) Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res 74(13):3535 3545. doi:http://dx.doi.org/10.1158/0008-5472.CAN-13-2893-T

Web End =10.1158/00085472.CAN132893T 132. Bellot G, GarciaMedina R, Gounon P, Chiche J, Roux D, Pouyssegur Jet al (2009) Hypoxiainduced autophagy is mediated through hypoxia inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 29(10):25702581. doi:http://dx.doi.org/10.1128/MCB.00166-09

Web End =10.1128/MCB.0016609 133. Dang CV, Kim JW, Gao P, Yustein J (2008) The interplay between MYC and HIF in cancer. Nat Rev Cancer 8(1):5156. doi:http://dx.doi.org/10.1038/nrc2274

Web End =10.1038/nrc2274 134. Myllyharju J, Koivunen P (2013) Hypoxiainducible factor prolyl

4hydroxylases: common and specic roles. Biol Chem 394(4):435448. doi:http://dx.doi.org/10.1515/hsz-2012-0328

Web End =10.1515/hsz20120328 135. Koivunen P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju

J (2007) Inhibition of hypoxiainducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282(7):45244532. doi:http://dx.doi.org/10.1074/jbc.M610415200

Web End =10.1074/jbc. http://dx.doi.org/10.1074/jbc.M610415200

Web End =M610415200 136. Ward PS, Patel J, Wise DR, AbdelWahab O, Bennett BD, Coller HA et al

(2010) The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglu tarate to 2hydroxyglutarate. Cancer Cell 17(3):225234. doi:http://dx.doi.org/10.1016/j.ccr.2010.01.020

Web End =10.1016/j. http://dx.doi.org/10.1016/j.ccr.2010.01.020

Web End =ccr.2010.01.020 137. Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12):931947. doi:http://dx.doi.org/10.1038/nrd4002

Web End =10.1038/ http://dx.doi.org/10.1038/nrd4002

Web End =nrd4002 138. Sabharwal SS, Schumacker PT (2014) Mitochondrial ROS in cancer: initiators, ampliers or an Achilles heel? Nat Rev Cancer 14(11):709721. doi:http://dx.doi.org/10.1038/nrc3803

Web End =10.1038/nrc3803 139. Castaldo SA, Freitas JR, Conchinha NV, Madureira PA (2016) The tumo rigenic roles of the cellular REDOX regulatory systems. Oxid Med Cell Longev 2016:8413032. doi:http://dx.doi.org/10.1155/2016/8413032

Web End =10.1155/2016/8413032 140. Liou GY, Storz P (2010) Reactive oxygen species in cancer. Free Radic

Res. 44(5):479496. doi:http://dx.doi.org/10.3109/10715761003667554

Web End =10.3109/10715761003667554 141. Tong L, Chuang CC, Wu S, Zuo L (2015) Reactive oxygen speciesin redox cancer therapy. Cancer Lett 367(1):1825. doi:http://dx.doi.org/10.1016/j.canlet.2015.07.008

Web End =10.1016/j. http://dx.doi.org/10.1016/j.canlet.2015.07.008

Web End =canlet.2015.07.008 142. Cabello CM, Bair WB 3rd, Wondrak GT (2007) Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 8(12):10221037143. Buchner FL, BuenodeMesquita HB, Linseisen J, Boshuizen HC,

Kiemeney LA, Ros MM et al (2010) Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Cause Cont 21(3):357371. doi:http://dx.doi.org/10.1007/s10552-009-9468-y

Web End =10.1007/s105520099468y 144. Ostrakhovitch EA (2011) Redox environment and its meaning for breast cancer cells fate. Curr Cancer Drug Targets 11(4):479495145. Glasauer A, Chandel NS (2014) Targeting antioxidants for cancer ther apy. Biochem Pharmacol 92(1):90101. doi:http://dx.doi.org/10.1016/j.bcp.2014.07.017

Web End =10.1016/j.bcp.2014.07.017 146. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V et al (2007) HIF dependent antitumorigenic eect of antioxidants in vivo. Cancer Cell 12(3):230238. doi:http://dx.doi.org/10.1016/j.ccr.2007.08.004

Web End =10.1016/j.ccr.2007.08.004 147. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Manseld KD et al (2005)

Mitochondrial complex III is required for hypoxiainduced ROS production and cellular oxygen sensing. Cell Metab 1(6):401408. doi:http://dx.doi.org/10.1016/j.cmet.2005.05.001

Web End =10.1016/j.cmet.2005.05.001 148. Manseld KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT et al

(2005) Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIFalpha activation. Cell Metab 1(6):393399. doi:http://dx.doi.org/10.1016/j.cmet.2005.05.003

Web End =10.1016/j.cmet.2005.05.003 149. RicoBautista E, Zhu W, Kitada S, Ganapathy S, Lau E, Krajewski S et al

(2013) Small moleculeinduced mitochondrial disruption directs

Ribas et al. Clin Trans Med (2016) 5:22

Page 21 of 24

prostate cancer inhibition via UPR signaling. Oncotarget 4(8):1212 1229. doi:http://dx.doi.org/10.18632/oncotarget.1130

Web End =10.18632/oncotarget.1130 150. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman

PJ et al (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549 1556. doi:http://dx.doi.org/10.1001/jama.2011.1437

Web End =10.1001/jama.2011.1437 151. Chandel NS, Tuveson DA (2014) The promise and perils of antioxidants for cancer patients. N Engl J Med 371(2):177178. doi:http://dx.doi.org/10.1056/NEJMcibr1405701

Web End =10.1056/ http://dx.doi.org/10.1056/NEJMcibr1405701

Web End =NEJMcibr1405701 152. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H (2000)

EUROSCAN, a randomized trial of vitamin A and Nacetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92(12):977986 153. Watson J (2013) Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3(1):120144. doi:http://dx.doi.org/10.1098/rsob.120144

Web End =10.1098/rsob.120144 154. Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG (2010) A nutri ent approach to prostate cancer prevention: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutri Cancer 62(7):896918. doi:http://dx.doi.org/10.1080/01635581.2010.509833

Web End =10.1 http://dx.doi.org/10.1080/01635581.2010.509833

Web End =080/01635581.2010.509833 155. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO (2014)

Antioxidants accelerate lung cancer progression in mice. Sci Trans Med 6(221):221. doi:http://dx.doi.org/10.1126/scitranslmed.3007653

Web End =10.1126/scitranslmed.3007653 156. LeGal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C et al (2015)

Antioxidants can increase melanoma metastasis in mice. Sci Trans Med 7(308):308. doi:http://dx.doi.org/10.1126/scitranslmed.aad3740

Web End =10.1126/scitranslmed.aad3740 157. Huang Y, Li W, Su ZY, Kong AN (2015) The complexity of the Nrf2 path way: beyond the antioxidant response. J Nutr Biochem 26(12):1401 1413. doi:http://dx.doi.org/10.1016/j.jnutbio.2015.08.001

Web End =10.1016/j.jnutbio.2015.08.001 158. Hayes JD, McMahon M, Chowdhry S, DinkovaKostova AT (2010) Cancer chemoprevention mechanisms mediated through the Keap1Nrf2 pathway. Antioxid Redox Signal 13(11):17131748. doi:http://dx.doi.org/10.1089/ars.2010.3221

Web End =10.1089/ http://dx.doi.org/10.1089/ars.2010.3221

Web End =ars.2010.3221 159. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M et al

(2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68(5):13031309. doi:http://dx.doi.org/10.1158/0008-5472.CAN-07-5003

Web End =10.1158/00085472.CAN075003 160. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY et al (2010) Onco genic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220(4):446451. doi:http://dx.doi.org/10.1002/path.2653

Web End =10.1002/path.2653 161. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M et al (2010) Loss of Kelchlike ECHassociated protein 1 function in pros tate cancer cells causes chemoresistance and radioresistance and pro motes tumor growth. Mol Cancer Ther 9(2):336346. doi:http://dx.doi.org/10.1158/1535-7163.MCT-09-0589

Web End =10.1158/1535 http://dx.doi.org/10.1158/1535-7163.MCT-09-0589

Web End =7163.MCT090589 162. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E,

Lloyd B et al (2011) Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10:37. doi:http://dx.doi.org/10.1186/1476-4598-10-37

Web End =10.1186/147645981037 163. Sasaki H, Suzuki A, Shitara M, Hikosaka Y, Okuda K, Moriyama S et al

(2013) Genotype analysis of the NRF2 gene mutation in lung cancer. Int J Mol Med 31(5):11351138. doi:http://dx.doi.org/10.3892/ijmm.2013.1324

Web End =10.3892/ijmm.2013.1324 164. Hu XF, Yao J, Gao SG, Wang XS, Peng XQ, Yang YT et al (2013) Nrf2 overexpression predicts prognosis and 5FU resistance in gastric cancer. Asian Pac J Cancer Prev 14(9):52315235165. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R et al (2016) Activation of the p62Keap1NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63(1):173184. doi:http://dx.doi.org/10.1002/hep.28251

Web End =10.1002/hep.28251 166. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K et al (2008)

Cancer related mutations in NRF2 impair its recognition by Keap1 Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105(36):1356813573. doi:http://dx.doi.org/10.1073/pnas.0806268105

Web End =10.1073/pnas.0806268105 167. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y et al (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12(3):213223. doi:http://dx.doi.org/10.1038/ncb2021

Web End =10.1038/ncb2021 168. Copple IM, Lister A, Obeng AD, Kitteringham NR, Jenkins RE, Layeld

R et al (2010) Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1Nrf2 cell defense pathway. J Biol Chem 285(22):1678216788. doi:http://dx.doi.org/10.1074/jbc.M109.096545

Web End =10.1074/jbc.M109.096545

169. Jain A, Lamark T, Sjottem E, Larsen KB, Awuh JA, Overvatn A et al

(2010) p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response elementdriven gene transcription. J Biol Chem 285(29):2257622591. doi:http://dx.doi.org/10.1074/jbc.M110.118976

Web End =10.1074/jbc.M110.118976 170. Taguchi K, Fujikawa N, Komatsu M, Ishii T, Unno M, Akaike T et al (2012)

Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci USA 109(34):1356113566. doi:http://dx.doi.org/10.1073/pnas.1121572109

Web End =10.1073/ http://dx.doi.org/10.1073/pnas.1121572109

Web End =pnas.1121572109 171. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T et al (2010) A noncanonical mechanism of Nrf2 activation by autophagy deciency: direct interaction between Keap1 and p62. Mol Cell Biol 30(13):3275 3285. doi:http://dx.doi.org/10.1128/MCB.00248-10

Web End =10.1128/MCB.0024810 172. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T et al (2007)

Homeostatic levels of p62 control cytoplasmic inclusion body forma tion in autophagydecient mice. Cell 131(6):11491163. doi:http://dx.doi.org/10.1016/j.cell.2007.10.035

Web End =10.1016/j. http://dx.doi.org/10.1016/j.cell.2007.10.035

Web End =cell.2007.10.035 173. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O et al (2011)

Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193(2):275284. doi:http://dx.doi.org/10.1083/jcb.201102031

Web End =10.1083/jcb.201102031 174. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese Ket al (2011) Oncogeneinduced Nrf2 transcription promotes ROS detox ication and tumorigenesis. Nature 475(7354):106109. doi:http://dx.doi.org/10.1038/nature10189

Web End =10.1038/ http://dx.doi.org/10.1038/nature10189

Web End =nature10189 175. Ashraan H, Czibik G, Bellahcene M, Aksentijevic D, Smith AC, Mitchell

SJ et al (2012) Fumarate is cardioprotective via activation of theNrf2 antioxidant pathway. Cell Metab 15(3):361371. doi:http://dx.doi.org/10.1016/j.cmet.2012.01.017

Web End =10.1016/j. http://dx.doi.org/10.1016/j.cmet.2012.01.017

Web End =cmet.2012.01.017 176. Kinch L, Grishin NV, Brugarolas J (2011) Succination of Keap1 and activa tion of Nrf2dependent antioxidant pathways in FHdecient papillary renal cell carcinoma type 2. Cancer Cell 20(4):418420. doi:http://dx.doi.org/10.1016/j.ccr.2011.10.005

Web End =10.1016/j. http://dx.doi.org/10.1016/j.ccr.2011.10.005

Web End =ccr.2011.10.005 177. Adam J, Hatipoglu E, OFlaherty L, Ternette N, Sahgal N, Lockstone Het al (2011) Renal cyst formation in Fh1decient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20(4):524537. doi:http://dx.doi.org/10.1016/j.ccr.2011.09.006

Web End =10.1016/j.ccr.2011.09.006 178. Villeneuve NF, Lau A, Zhang DD (2010) Regulation of the Nrf2Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullinring ubiquitin ligases. Antioxid Redox Signal 13(11):1699 1712. doi:http://dx.doi.org/10.1089/ars.2010.3211

Web End =10.1089/ars.2010.3211 179. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y et al (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29(6):12351243. doi:http://dx.doi.org/10.1093/carcin/bgn095

Web End =10.1093/carcin/bgn095 180. Shelton P, Jaiswal AK (2013) The transcription factor NFE2related factor 2 (Nrf2): a protooncogene? FASEB J 27(2):414423. doi:http://dx.doi.org/10.1096/fj.12-217257

Web End =10.1096/ http://dx.doi.org/10.1096/fj.12-217257

Web End =fj.12217257 181. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao

Z et al (2015) Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527(7577):186191. doi:http://dx.doi.org/10.1038/nature15726

Web End =10.1038/nature15726 182. Nguyen A, Loo JM, Mital R, Weinberg EM, Man FY, Zeng Z et al (2016)

PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. J Clin Invest 126(2):681694. doi:http://dx.doi.org/10.1172/JCI83587

Web End =10.1172/ http://dx.doi.org/10.1172/JCI83587

Web End =JCI83587 183. Goh J, Enns L, Fatemie S, Hopkins H, Morton J, PettanBrewer C et al

(2011) Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer 11:191. doi:http://dx.doi.org/10.1186/1471-2407-11-191

Web End =10.1186/1471240711191 184. Porporato PE, Payen VL, PerezEscuredo J, De Saedeleer CJ, Danhier P,

Copetti T et al (2014) A mitochondrial switch promotes tumor metasta sis. Cell Rep 8(3):754766. doi:http://dx.doi.org/10.1016/j.celrep.2014.06.043

Web End =10.1016/j.celrep.2014.06.043 185. Nazarewicz RR, Dikalova A, Bikineyeva A, Ivanov S, Kirilyuk IA, Grigorev

IA et al (2013) Does scavenging of mitochondrial superoxide attenu ate cancer prosurvival signaling pathways? Antioxid Redox Signal 19(4):344349. doi:http://dx.doi.org/10.1089/ars.2013.5185

Web End =10.1089/ars.2013.5185 186. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez

M et al (2010) Mitochondrial metabolism and ROS generation are essential for Krasmediated tumorigenicity. Proc Natl Acad Sci USA 107(19):87888793. doi:http://dx.doi.org/10.1073/pnas.1003428107

Web End =10.1073/pnas.1003428107 187. Matsumoto K, Imagawa S, Obara N, Suzuki N, Takahashi S, Nagasawa

T et al (2006) 2Oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing

Ribas et al. Clin Trans Med (2016) 5:22

Page 22 of 24

hypoxiainducible factor1alpha and inhibits angiogenesis. J Cell Physiol 209(2):333340. doi:http://dx.doi.org/10.1002/jcp.20733

Web End =10.1002/jcp.20733 188. Kaelin WG Jr (2011) Cancer and altered metabolism: potential impor tance of hypoxiainducible factor and 2oxoglutaratedependent dioxy genases. Cold Spring Harb Symp Quant Biol 76:335345. doi:http://dx.doi.org/10.1101/sqb.2011.76.010975

Web End =10.1101/ http://dx.doi.org/10.1101/sqb.2011.76.010975

Web End =sqb.2011.76.010975 189. Bosch M, Mari M, Gross SP, FernandezCheca JC, Pol A (2011) Mitochon drial cholesterol: a connection between caveolin, metabolism, and disease. Traffic 12(11):14831489. doi:http://dx.doi.org/10.1111/j.1600-0854.2011.01259.x

Web End =10.1111/j.16000854.2011.01259.x 190. Colell A, Fernandez A, FernandezCheca JC (2009) Mitochondria, choles terol and amyloid beta peptide: a dangerous trio in Alzheimer disease. J Bioenerg Biomembr 41(5):417423. doi:http://dx.doi.org/10.1007/s10863-009-9242-6

Web End =10.1007/s1086300992426 191. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani

M et al (2005) Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1(6):409414. doi:http://dx.doi.org/10.1016/j.cmet.2005.05.002

Web End =10.1016/j. http://dx.doi.org/10.1016/j.cmet.2005.05.002

Web End =cmet.2005.05.002 192. Rotili D, Mai A (2011) Targeting histone demethylases: a newavenue for the ght against Cancer. Genes Cancer 2(6):663679. doi:http://dx.doi.org/10.1177/1947601911417976

Web End =10.1177/1947601911417976 193. Tsujimoto Y, Yunis J, OnoratoShowe L, Erikson J, Nowell PC, Croce CM

(1984) Molecular cloning of the chromosomal breakpoint of Bcell lymphomas and leukemias with the t(11;14) chromosome transloca tion. Science 224(4656):14031406194. Pegoraro L, Palumbo A, Erikson J, Falda M, Giovanazzo B, Emanuel BS et al (1984) A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute Bcell leukemia. Proc Natl Acad Sci USA 81(22):71667170195. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al (2010) The landscape of somatic copynumber alteration across human cancers. Nature 463(7283):899905. doi:http://dx.doi.org/10.1038/nature08822

Web End =10.1038/nature08822 196. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al

(2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471(7336):110114. doi:http://dx.doi.org/10.1038/nature09779

Web End =10.1038/nature09779 197. Wang C, Youle RJ (2012) Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl1s inhibitory eect on Bak. Onco gene 31(26):31773189. doi:http://dx.doi.org/10.1038/onc.2011.497

Web End =10.1038/onc.2011.497 198. Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L et al (2013)

BID preferentially activates BAK while BIM preferentially activatesBAX, aecting chemotherapy response. Mol Cell 51(6):751765. doi:http://dx.doi.org/10.1016/j.molcel.2013.08.048

Web End =10.1016/j.molcel.2013.08.048 199. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL2 family members. Cancer Cell 9(5):351365. doi:http://dx.doi.org/10.1016/j.ccr.2006.03.027

Web End =10.1016/j.ccr.2006.03.027 200. Lopez J, Tait SW (2015) Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer 112(6):957962. doi:http://dx.doi.org/10.1038/bjc.2015.85

Web End =10.1038/bjc.2015.85 201. Wickramasekera NT, Das GM (2014) Tumor suppressor p53 and estro gen receptors in nuclearmitochondrial communication. Mitochon drion 16:2637. doi:http://dx.doi.org/10.1016/j.mito.2013.10.002

Web End =10.1016/j.mito.2013.10.002 202. Dashzeveg N, Yoshida K (2015) Cell death decision by p53 via controlof the mitochondrial membrane. Cancer Lett 367(2):108112. doi:http://dx.doi.org/10.1016/j.canlet.2015.07.019

Web End =10.1016/j.canlet.2015.07.019 203. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149(7):15361548. doi:http://dx.doi.org/10.1016/j.cell.2012.05.014

Web End =10.1016/j.cell.2012.05.014 204. Guo X, Sesaki H, Qi X (2014) Drp1 stabilizes p53 on the mitochondria to trigger necrosis under oxidative stress conditions in vitro and in vivo. Biochem J 461(1):137146. doi:http://dx.doi.org/10.1042/BJ20131438

Web End =10.1042/BJ20131438 205. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A et al

(2008) Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 7(19):30563061206. Soussi T, Wiman KG (2015) TP53: an oncogene in disguise. Cell Death

Dier 22(8):12391249. doi:http://dx.doi.org/10.1038/cdd.2015.53

Web End =10.1038/cdd.2015.53 207. Colell A, Ricci JE, Tait S, Milasta S, Maurer U, BouchierHayes L et al (2007)

GAPDH and autophagy preserve survival after apoptotic cytochromec release in the absence of caspase activation. Cell 129(5):983997. doi:http://dx.doi.org/10.1016/j.cell.2007.03.045

Web End =10.1016/j.cell.2007.03.045 208. Deshmukh M, Kuida K, Johnson EM Jr (2000) Caspase inhibition extends the commitment to neuronal death beyond cytochrome c release to the point of mitochondrial depolarization. J Cell Biol. 150(1):131143

209. Gama V, Swahari V, Schafer J, Kole AJ, Evans A, Huang Y et al (2014) The

E3 ligase PARC mediates the degradation of cytosolic cytochrome cto promote survival in neurons and cancer cells. Sci Signal. 7(334):67. doi:http://dx.doi.org/10.1126/scisignal.2005309

Web End =10.1126/scisignal.2005309 210. Tait SW, Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11(9):621632. doi:http://dx.doi.org/10.1038/nrm2952

Web End =10.1038/nrm2952 211. Tang HL, Tang HM, Mak KH, Hu S, Wang SS, Wong KM et al (2012) Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol Biol Cell 23(12):22402252. doi:http://dx.doi.org/10.1091/mbc.E11-11-0926

Web End =10.1091/mbc.E11110926 212. Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado

ME et al (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell 57(5):860872. doi:http://dx.doi.org/10.1016/j.molcel.2015.01.018

Web End =10.1016/j.molcel.2015.01.018 213. Liu X, He Y, Li F, Huang Q, Kato TA, Hall RP et al (2015) Caspase3 pro motes genetic instability and carcinogenesis. Mol Cell 58(2):284296. doi:http://dx.doi.org/10.1016/j.molcel.2015.03.003

Web End =10.1016/j.molcel.2015.03.003 214. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X et al (2012) ATF4 regulates

MYCmediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22(5):631644. doi:http://dx.doi.org/10.1016/j.ccr.2012.09.021

Web End =10.1016/j.ccr.2012.09.021 215. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Ham ilton SK et al (2007) Novel mechanism of inhibition of rat kidney type glutaminase by bis2(5phenylacetamido1,2,4thiadiazol2yl) ethyl sulfide (BPTES). Biochem J 406(3):407414. doi:http://dx.doi.org/10.1042/BJ20070039

Web End =10.1042/ http://dx.doi.org/10.1042/BJ20070039

Web End =BJ20070039 216. Ahluwalia GS, Grem JL, Hao Z, Cooney DA (1990) Metabolism and action of amino acid analog anticancer agents. Pharmacol Therap 46(2):243271217. Ovejera AA, Houchens DP, Catane R, Sheridan MA, Muggia FM (1979)

Efficacy of 6diazo5oxoLnorleucine and N[Ngammaglutamyl6di azo5oxonorleucinyl]6diazo5oxonorleucine against experimental tumors in conventional and nude mice. Cancer Res 39(8):32203224 218. Li B, Simon MC (2013) Molecular Pathways: targeting MYCinduced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 19(21):58355841. doi:http://dx.doi.org/10.1158/1078-0432.CCR-12-3629

Web End =10.1158/10780432.CCR123629 219. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM et al (2010)

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107(5):20372042. doi:http://dx.doi.org/10.1073/pnas.0914433107

Web End =10.1073/pnas.0914433107 220. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WMet al (2009) LDHA inhibition, a therapeutic strategy for treatmentof hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8(3):626635. doi:http://dx.doi.org/10.1158/1535-7163.MCT-08-1049

Web End =10.1158/15357163.MCT081049 221. Wang ZY, Loo TY, Shen JG, Wang N, Wang DM, Yang DP et al (2012)

LDHA silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res Treat 131(3):791800. doi:http://dx.doi.org/10.1007/s10549-011-1466-6

Web End =10.1007/ http://dx.doi.org/10.1007/s10549-011-1466-6

Web End =s1054901114666 222. Nilsson LM, Forshell TZ, Rimpi S, Kreutzer C, Pretsch W, Bornkamm GW et al (2012) Mouse genetics suggests cellcontext dependency for Mycregulated metabolic enzymes during tumorigenesis. PLoS Genet 8(3):e1002573. doi:http://dx.doi.org/10.1371/journal.pgen.1002573

Web End =10.1371/journal.pgen.1002573 223. Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W et al (2014)

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res 74(3):908920. doi:http://dx.doi.org/10.1158/0008-5472.CAN-13-2034

Web End =10.1158/00085472.CAN132034 224. Bonnet S, Archer SL, AllalunisTurner J, Haromy A, Beaulieu C, Thompson

R et al (2007) A mitochondriaK+ channel axis is suppressed in cancer

and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11(1):3751. doi:http://dx.doi.org/10.1016/j.ccr.2006.10.020

Web End =10.1016/j.ccr.2006.10.020 225. Dasgupta B, Chhipa RR (2015) Evolving lessons on the complex roleof AMPK in normal physiology and cancer. Trends Pharmacol Sci. doi:http://dx.doi.org/10.1016/j.tips.2015.11.007

Web End =10.1016/j.tips.2015.11.007 226. Cazzaniga M, Bonanni B (2015) Breast Cancer Metabolism and Mito chondrial Activity: the Possibility of Chemoprevention with Metformin. BioMed research Int 2015:972193. doi:http://dx.doi.org/10.1155/2015/972193

Web End =10.1155/2015/972193 227. Jara JA, LopezMunoz R (2015) Metformin and cancer: between the bioenergetic disturbances and the antifolate activity. Pharmacol Res 101:102108. doi:http://dx.doi.org/10.1016/j.phrs.2015.06.014

Web End =10.1016/j.phrs.2015.06.014

Ribas et al. Clin Trans Med (2016) 5:22

Page 23 of 24

228. Morales DR, Morris AD (2015) Metformin in cancer treat ment and prevention. Annu Rev Med 66:1729. doi:http://dx.doi.org/10.1146/annurev-med-062613-093128

Web End =10.1146/ http://dx.doi.org/10.1146/annurev-med-062613-093128

Web End =annurevmed062613093128

229. Chiavarina B, WhitakerMenezes D, MartinezOutschoorn UE, Witkiewicz

AK, Birbe R, Howell A et al (2011) Pyruvate kinase expression (PKM1 and PKM2) in cancerassociated broblasts drives stromal nutrient production and tumor growth. Cancer Biol Ther 12(12):11011113. doi:http://dx.doi.org/10.4161/cbt.12.12.18703

Web End =10.4161/cbt.12.12.18703 230. Del Barco S, VazquezMartin A, Cu S, OliverasFerraros C, BoschBarrera J, Joven J et al (2011) Metformin: multifaceted protection against cancer. Oncotarget 2(12):896917. doi:http://dx.doi.org/10.18632/oncotarget.387

Web End =10.18632/oncotarget.387 231. Zhang X, Fryknas M, Hernlund E, Fayad W, De Milito A, Olofsson MHet al (2014) Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenviron ments. Nat Commun 5:3295. doi:http://dx.doi.org/10.1038/ncomms4295

Web End =10.1038/ncomms4295 232. Rohlena J, Dong LF, Ralph SJ, Neuzil J (2011) Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid Redox Signal 15(12):29512974. doi:http://dx.doi.org/10.1089/ars.2011.3990

Web End =10.1089/ars.2011.3990 233. CorazaoRozas P, Guerreschi P, Jendoubi M, Andre F, Jonneaux A,

Scalbert C et al (2013) Mitochondrial oxidative stress is the Achilles heel of melanoma cells resistant to Brafmutant inhibitor. Oncotarget 4(11):19861998. doi:http://dx.doi.org/10.18632/oncotarget.1420

Web End =10.18632/oncotarget.1420 234. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli

BA et al (2005) An inhibitor of Bcl2 family proteins induces regression of solid tumours. Nature 435(7042):677681. doi:http://dx.doi.org/10.1038/nature03579

Web End =10.1038/nature03579 235. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al (2008)

ABT263: a potent and orally bioavailable Bcl2 family inhibitor. Cancer Res 68(9):34213428. doi:http://dx.doi.org/10.1158/0008-5472.CAN-07-5836

Web End =10.1158/00085472.CAN075836 236. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ et al (2011) BclxLinhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plate lets. Blood 118(6):16631674. doi:http://dx.doi.org/10.1182/blood-2011-04-347849

Web End =10.1182/blood201104347849 237. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling

MR et al (2011) Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 208(10):20172031. doi:http://dx.doi.org/10.1084/jem.20110750

Web End =10.1084/jem.20110750 238. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen Jet al (2013) ABT199, a potent and selective BCL2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202208. doi:http://dx.doi.org/10.1038/nm.3048

Web End =10.1038/nm.3048 239. Ng SY, Davids MS (2014) Selective Bcl2 inhibition to treat chronic lymphocytic leukemia and nonHodgkin lymphoma. Clin Adv Hematol Oncol 12(4):224229240. Fresquet V, Rieger M, Carolis C, GarciaBarchino MJ, MartinezCliment JA

(2014) Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT199 in lymphoma. Blood 123(26):41114119. doi:http://dx.doi.org/10.1182/blood-2014-03-560284

Web End =10.1182/blood201403560284 241. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PEet al (2006) The BH3 mimetic ABT737 targets selective Bcl2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl1 is neutralized. Cancer Cell 10(5):389399. doi:http://dx.doi.org/10.1016/j.ccr.2006.08.027

Web End =10.1016/j.ccr.2006.08.027 242. Modugno M, Ban P, Gasparri F, Borzilleri R, Carter P, Cornelius L et al

(2015) Mcl1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Exp Cell Res 332(2):267277. doi:http://dx.doi.org/10.1016/j.yexcr.2014.11.022

Web End =10.1016/j. http://dx.doi.org/10.1016/j.yexcr.2014.11.022

Web End =yexcr.2014.11.022 243. Vela L, Marzo I (2015) Bcl2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol 23:7481. doi:http://dx.doi.org/10.1016/j.coph.2015.05.014

Web End =10.1016/j.coph.2015.05.014 244. Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR,

Koss B et al (2012) A competitive stapled peptide screen identi fies a selective small molecule that overcomes MCL1dependent leukemia cell survival. Chem Biol 19(9):11751186. doi:http://dx.doi.org/10.1016/j.chembiol.2012.07.018

Web End =10.1016/j. http://dx.doi.org/10.1016/j.chembiol.2012.07.018

Web End =chembiol.2012.07.018 245. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al (2015)

Potent and selective smallmolecule MCL1 inhibitors demonstrate ontarget cancer cell killing activity as single agents and in combina tion with ABT263 (navitoclax). Cell Death Dis 6:e1590. doi:http://dx.doi.org/10.1038/cddis.2014.561

Web End =10.1038/ http://dx.doi.org/10.1038/cddis.2014.561

Web End =cddis.2014.561 246. Thomas RL, Gustafsson AB (2013) MCL1 is critical for mitochondrial function and autophagy in the heart. Autophagy 9(11):19021903. doi:http://dx.doi.org/10.4161/auto.26168

Web End =10.4161/auto.26168

247. Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X et al (2013) miR135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 19(4):677683. doi:http://dx.doi.org/10.1007/s12253-013-9630-4

Web End =10.1007/ http://dx.doi.org/10.1007/s12253-013-9630-4

Web End =s1225301396304

248. Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L et al

(2014) Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res 20(17):45204531. doi:http://dx.doi.org/10.1158/1078-0432.CCR-14-0259

Web End =10.1158/10780432. http://dx.doi.org/10.1158/1078-0432.CCR-14-0259

Web End =CCR140259 249. Chonghaile TN, Roderick JE, Gleneld C, Ryan J, Sallan SE, Silverman LB et al (2014) Maturation stage of Tcell acute lymphoblastic leukemia determines BCL2 versus BCLXL dependence and sensitivity to ABT 199. Cancer Discov 4(9):10741087. doi:http://dx.doi.org/10.1158/2159-8290.CD-14-0353

Web End =10.1158/21598290.CD140353 250. Marchenko ND, Zaika A, Moll UM (2000) Death signalinduced localiza tion of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275(21):1620216212251. Liu J, Wang Z (2015) Increased oxidative stress as a selective anticancer therapy. Oxid Med Cell Longev 2015:294303. doi:http://dx.doi.org/10.1155/2015/294303

Web End =10.1155/2015/294303 252. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65(18):84558460. doi:http://dx.doi.org/10.1158/0008-5472.CAN-05-1162

Web End =10.1158/00085472.CAN051162 253. Hasino BB, Wu X, Yadav AA, Patel D, Zhang H, Wang DS et al (2015)

Cellular mechanisms of the cytotoxicity of the anticancer drug eles clomol and its complex with Cu(II). Biochem Pharmacol 93(3):266276. doi:http://dx.doi.org/10.1016/j.bcp.2014.12.008

Web End =10.1016/j.bcp.2014.12.008 254. Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang Met al (2008) Elesclomol induces cancer cell apoptosis through oxida tive stress. Mol Cancer Ther 7(8):23192327. doi:http://dx.doi.org/10.1158/1535-7163.MCT-08-0298

Web End =10.1158/15357163. http://dx.doi.org/10.1158/1535-7163.MCT-08-0298

Web End =MCT080298 255. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al

(2006) Selective killing of oncogenically transformed cells through a ROSmediated mechanism by betaphenylethyl isothiocyanate. Cancer Cell 10(3):241252. doi:http://dx.doi.org/10.1016/j.ccr.2006.08.009

Web End =10.1016/j.ccr.2006.08.009 256. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10(3):175176. doi:http://dx.doi.org/10.1016/j.ccr.2006.08.015

Web End =10.1016/j. http://dx.doi.org/10.1016/j.ccr.2006.08.015

Web End =ccr.2006.08.015 257. Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancercells: how many ways can curry kill tumor cells selectively? AAPS J 11(3):495510. doi:http://dx.doi.org/10.1208/s12248-009-9128-x

Web End =10.1208/s122480099128x 258. Yue P, Zhou Z, Khuri FR, Sun SY (2006) Depletion of intracellular glu tathione contributes to JNKmediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl 2cyano3, 12dioxooleana1, 9dien28oate (CDDOMe). Cancer Biol Ther 5(5):492497259. Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257(22):1370413712260. Sobhakumari A, LoveHoman L, Fletcher EV, Martin SM, Parsons AD,

Spitz DR et al (2012) Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabo lism. PLoS One 7(10):e48175. doi:http://dx.doi.org/10.1371/journal.pone.0048175

Web End =10.1371/journal.pone.0048175 261. Lo M, Ling V, Low C, Wang YZ, Gout PW (2010) Potential use of the antiinammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol 17(3):916262. Gout PW, Buckley AR, Simms CR, Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c) cystine transporter: a new action for an old drug. Leukemia

15(10):16331640

263. Samudio I, Konopleva M, Hail N Jr, Shi YX, McQueen T, Hsu T et al (2005)

2Cyano3,12dioxooleana1,9dien28imidazolide (CDDOIm) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 280(43):3627336282. doi:http://dx.doi.org/10.1074/jbc.M507518200

Web End =10.1074/jbc.M507518200 264. Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M et al

(2008) Inhibition of mitochondrial metabolism by methyl2cyano 3,12dioxooleana1,9diene28oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther 7(5):11301139. doi:http://dx.doi.org/10.1158/1535-7163.MCT-07-0553

Web End =10.1158/15357163.MCT070553 265. Chen G, Chen Z, Hu Y, Huang P (2011) Inhibition of mitochondrial respiration and rapid depletion of mitochondrial glutathione by betaphenethyl isothiocyanate: mechanisms for antileukemia activity. Antioxid Redox Signal 15(12):29112921. doi:http://dx.doi.org/10.1089/ars.2011.4170

Web End =10.1089/ars.2011.4170

Ribas et al. Clin Trans Med (2016) 5:22

Page 24 of 24

266. Bezerra DP, Militao GC, de Castro FO, Pessoa C, de Moraes MO, Silveira

ER et al (2007) Piplartine induces inhibition of leukemia cell prolifera tion triggering both apoptosis and necrosis pathways. Toxicol In Vitro 21(1):18. doi:http://dx.doi.org/10.1016/j.tiv.2006.07.007

Web End =10.1016/j.tiv.2006.07.007 267. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X et al (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475(7355):231234. doi:http://dx.doi.org/10.1038/nature10167

Web End =10.1038/nature10167 268. Tateishi Y, Sasabe E, Ueta E, Yamamoto T (2008) Ionizing irradiation induces apoptotic damage of salivary gland acinar cells via NADPH oxidase 1dependent superoxide generation. Biochem Biophys Res Commun 366(2):301307. doi:http://dx.doi.org/10.1016/j.bbrc.2007.11.039

Web End =10.1016/j.bbrc.2007.11.039 269. Yamamori T, Yasui H, Yamazumi M, Wada Y, Nakamura Y, Nakamura Het al (2012) Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic Biol Med 53(2):260270. doi:http://dx.doi.org/10.1016/j.freeradbiomed.2012.04.033

Web End =10.1016/j.freeradbiomed.2012.04.033 270. Ghosh P, Singha Roy S, Basu A, Bhattacharjee A, Bhattacharya S (2015)

Sensitization of cisplatin therapy by a naphthalimide based organosele nium compound through modulation of antioxidant enzymes and p53 mediated apoptosis. Free Radic Res 49(4):453471. doi:http://dx.doi.org/10.3109/10715762.2015.1012079

Web End =10.3109/107157 http://dx.doi.org/10.3109/10715762.2015.1012079

Web End =62.2015.1012079 271. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008)

Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100(11):773 783. doi:http://dx.doi.org/10.1093/jnci/djn148

Web End =10.1093/jnci/djn148

272. Filippova M, Filippov V, Williams VM, Zhang K, Kokoza A, Bashkirova

S et al (2014) Cellular levels of oxidative stress aect the response of cervical cancer cells to chemotherapeutic agents. BioMed research international. 2014:574659. doi:http://dx.doi.org/10.1155/2014/574659

Web End =10.1155/2014/574659 273. GarciaRuiz C, Morales A, FernandezCheca JC (2012) Statins and pro tein prenylation in cancer cell biology and therapy. Anticancer Agents Med Chem 12(4):303315274. Elson CE, Peffley DM, Hentosh P, Mo H (1999) Isoprenoidmediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 221(4):294311275. Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role ofstatins in cancer therapy. Oncologist 11(3):306315. doi:http://dx.doi.org/10.1634/theoncologist.11-3-306

Web End =10.1634/ http://dx.doi.org/10.1634/theoncologist.11-3-306

Web End =theoncologist.113306 276. Elsayed RK, Evans JD (2008) Emerging lipidlowering drugs: squalene synthase inhibitors. Expert Opin Emerg Drugs 13(2):309322. doi:http://dx.doi.org/10.1517/14728214.13.2.309

Web End =10.1517/14728214.13.2.309 277. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ,

Buser CA et al (2001) Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 61(24):87588768278. Sun J, Qian Y, Hamilton AD, Sebti SM (1998) Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibitionof oncogenic KRas prenylation but each alone is sufficient to sup press human tumor growth in nude mouse xenografts. Oncogene 16(11):14671473. doi:http://dx.doi.org/10.1038/sj.onc.1201656

Web End =10.1038/sj.onc.1201656